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Abstract 
Gastrointestinal symptoms such as diarrhea, cramping, nausea and gastric pain occur frequently in runners 
during training and competitions. The mechanisms leading to the distress are not fully understood, nor the 
reason why some remain asymptomatic. However, hyperthermia induced by exercise elevation of core 
temperature and oxidative damage due to reduced gastric blood flow have been postulated to affect the 
intestinal epithelial cells. Both sources of stress disrupt the binding of the epithelial tight junction proteins and 
increase permeability of the membrane to luminal endotoxins. Endotoxins reaching the blood stream through 
leaky tight junctions lead to an inflammatory response mediated by cytokines. These mechanisms may underlie 
the gastrointestinal symptoms often experienced by endurance athletes. 
 
The aim of this study was to measure running-induced changes in intestinal permeability and inflammatory 
markers and investigate their association with gastrointestinal symptoms. A secondary objective was to inspect 
possible correlations between gastrointestinal symptom occurrence and intake of certain nutrients. 
A total of 17 active runners were allocated into a control group (asymptomatic) or a symptomatic group based 
on a symptom history questionnaire and completed a 90-minute running test. Intestinal permeability at 
baseline and after the run were assessed via urine recovery of orally administered Iohexol .  LPS (endotoxin) 
and zonulin concentrations were determined from serum samples. Participants kept a food diary for three days 
before each measurement and filled out a symptom questionnaire after the run.  
 
No significant difference was found in intestinal permeability between symptomatic and asymptomatic runners 
either at rest or following strenuous exercise. However, both groups experienced a significant increase in 
intestinal permeability from baseline to after running. LPS concentrations were significantly higher at baseline 
in the symptomatic group. This may explain the higher symptom occurrence in the symptomatic group. Zonulin 
levels were higher in control group than symptom group after the run. Zonulin concentration was also higher in 
the control group after the run compared to baseline. The symptom group reported more stomach pain and 
stool changes after running compared to controls. Comparison of average intake of various nutrients between 
the two groups showed no significant differences, indicating an individual predisposition as the cause of 
symptoms rather than diet alone. The lack of difference in intestinal permeability between the groups 
combined with the difference in symptom occurrence indicates that intestinal permeability changes alone do 
not account for symptom development. A possible factor may be individual differences in intestinal mucosa 
repair ability or some underlying pathology.  
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1. Review of Literature 
1.1 Protective role of gastrointestinal barrier 
 
The gastrointestinal epithelium is known for its role in digestion and efficient uptake of nutrients. 
It forms a selectively permeable barrier, letting certain substances like nutrients, water, and 
electrolytes permeate while excluding unwanted luminal contents such as bacterial toxins. It is a 
single-cell layer and forms the largest and most important barrier against the external 
environment (Groschwitz and Hogan, 2009). The gastrointestinal epithelial barrier is maintained 
by formation of protein-protein networks that mechanically link together neighboring epithelial 
cells and prevent free passage of molecules between these cells. The adhesive junctional 
complexes connecting neighboring cells consist of desmosomes, adherens junctions, and tight 
junctions and are formed from protein networks of interacting transmembrane proteins 
(Groschwitz and Hogan, 2009). The transmembrane proteins interact both extracellularly and 
intracellularly with adaptor proteins that link to the cytoskeleton (Groschwitz and Hogan, 2009). 
Of these complexes, tight junctions (Figure 1, p.5) are the most important in the context of 
intestinal permeability.  
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Figure 1. The intestinal epithelium consists of a single layer of polarized epithelial cells. Intestinal epithelial 
junctional complexes connecting neighboring cells consist of desmosomes, adherens junctions, and tight junctions. 
Desmosomes are localized dense plaques that are connected to keratin filaments. Adherens and tight junctions both 
consist of transcellular proteins connected intracellularly through adaptor proteins to the actin cytoskeleton 
(Groschwitz and Hogan, 2009). 
 
The luminal contents of the intestine harbor products that can both initiate and sustain 
inflammatory responses in the intestinal epithelium. Such substances may include food antigens, 
bile, hydrolytic enzymes, and endotoxin (lipopolysaccharide, LPS) (Lambert, 2009). Several 
other stresses have been suggested to damage the integrity of the barrier, including psychological 
stress (Söderholm and Perdue, 2001), heat stress (Moseley et al., 1994), certain medications 
(Lambert et al., 2007), and exercise (Pals et al., 1997). In addition to enterocyte membranes and 
tight junctions joining the neighboring epithelial cells and forming the gastrointestinal barrier, 
mucus and tissue macrophages also contribute to barrier function, or the ability to control the 
passage of substances from the gut lumen to circulation, by restricting passage of unwanted 
substances to the circulatory system (Lambert, 2009). Loss of the gastrointestinal barrier 
integrity leads to increased intestinal permeability which refers to the relative ease of unmediated 
passage of substances through the epithelial wall into blood circulation. It typically refers to the 
nonmediated diffusion of large normally restricted particles of >150 Da across the epithelial 
barrier and into blood circulation (Lambert, 2009). Although a low level of permeability is 
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present normally in the intestine, the gastrointestinal barrier and immune system together prevent 
entry and damage by pathogens (Lambert, 2009).  
 
1.1.1 Paracellular and transcellular transport 
 
Two modes of transport have been established for intestinal permeation as shown in Figure 2 
(p.8). These include the transcellular route, where substances cross the epithelial barrier through 
the cells with transport predominantly regulated by selective transporters for amino acids, 
electrolytes, short-chain fatty acids, and sugars and the paracellular route, where substances 
diffuse between neighboring epithelial cells with transport mediated by tight junctions 
(Groschwitz and Hogan, 2009). In a transcellular pathway, compounds must cross the 
microvillus membrane of the epithelial cell by active transport or endocytosis (de Punder and 
Pruimboom, 2015). However, water-soluble substances cannot cross lipid bilayer membranes 
and therefore the paracellular pathway mediated by tight junctions becomes an important means 
of transport for water, solutes, and minerals across the intestinal barrier (Kapus and Szászi, 2006; 
Turner et al., 1997). Tight junctions are an important part of several types of absorptive and 
secretory epithelia. In the gastrointestinal system, tight junctions act as gatekeepers, forming the 
permeability barrier by controlling the passage of ions and larger molecules between the 
neighboring cells. The multi-protein epithelial tight junction complexes are composed of 
transmembrane proteins, such as claudin, peripheral membrane proteins, such as zona occludens, 
and regulatory molecules including kinases (Turner, 2009). The tight junction is found on the 
most apical region of the junction and forms a very tight contact between neighboring cells. 
Permeation studies using tracers have clearly demonstrated that the tight junction forms the site 
where paracellular diffusion of particles is restricted (Magnuson et al., 1978). One hypothesis to 
explain the differences in permeability between substances of different characteristics indicates 
that smaller molecules find the greatest number of suitable pores in the epithelia and cross the 
barrier in greater numbers than larger molecules which would be unable to pass through the 
pores (Meddings, 1997). These small hydrophilic pores are believed to represent integral 
membrane proteins of the lipid bilayer (Meddings, 1997). Thus, both large and small (<300nm) 
molecules cross the epithelial barrier by diffusion between cells but only small molecules can 
take advantage of the transcellular pathway (Meddings, 1997). This has been demonstrated 
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through permeability experiments of small water-soluble substances across rat small intestine 
which demonstrated a low abundance pathway through which large particles can move and 
which is not size dependent (Meddings, 1997). In other words, larger particles can move through 
a pathway that is not dependent on the size of the molecule while a second pathway 
characterized in the experiments is a more numerous but size dependent pathway (Meddings, 
1997). Thus, smaller molecules can move across the membrane more rapidly as they can take 
advantage of smaller pores. These pathways correspond to the paracellular and transcellular 
modes of transit and are supported by other experiments. Maxton et al. (1986) demonstrated that 
damage to the epithelium through use of detergents led to increased passage through large 
pathways with no change in small pathway. This supports the notion that damage to epithelial 
tight junctions increases permeability to large molecules while the diffusion of small molecules 
across the epithelial cell membranes is unchanged (Meddings, 1997). In turn, the active uptake of 
glucose, sodium, and water is mediated by sodium-dependent glucose co-transporters (SGLTs) 
(Turner, 2000). The transcellular absorption of glucose and sodium to the basolateral membrane 
by transporters opens up the paracellular pathway structure and allows the diffusion of water and 
small nutrients by creating an osmotic gradient (Turner, 2000). Tight junctions limit solute 
transit in the paracellular pathway, which is typically more permeable than the transcellular 
pathway. Therefore, tight junctions become the rate-limiting step in solute transport across the 
epithelium and the principal determinant of mucosal permeability (Turner, 2009).  
Two routes of paracellular transport exist and depend on size and charge selectivity. One route 
allows permeation of large solutes including proteins and bacterial endotoxins (Van Itallie et al., 
2008; Watson et al., 2005). The exact size at which solutes are excluded from this pathway has 
not yet been determined although it is clear that whole bacteria are too large to pass (Turner, 
2009). As might be expected from a pathway which allows large solutes to pass, this pathway is 
not dependent on charge (Turner, 2009) and cytokines, including interferon-gamma (IFN-γ)and 
tumor necrosis factor α (TNF-α) may increase passage across the barrier (Clayburgh et al., 2006; 
Wang et al., 2005; Watson et al., 2005). A second route of paracellular permeation is defined by 
charge dependent small pores which are thought to be mediated by tight junction claudin proteins 
which are the primary determinants of charge selectivity (Amasheh et al., 2002; Colegio et al., 
2003; Simon et al., 1999). Thus, tight junctions exhibit both size and charge sensitivity and these 
properties can be influenced by physiological and pathological factors (Turner, 2009). In 
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addition to their role as gate-keepers in paracellular transport, tight junctions also participate in 
transcellular transport by maintaining the polarization of the apical and basolateral domains in 
epithelial cells (Gumbiner and Louvard, 1985; Simons and Fuller, 1985). This polarization 
allows the diffusion of substrates across the epithelial cell membrane, as transport proteins are 
located appropriately for their function.  
 
Figure 2. Pathways of epithelial permeability. In transcellular permeation solutes or water move through intestinal 
epithelial cells. In paracellular permeation solutes move in the intercellular space between epithelial cells and 
permeation is regulated by tight junctions found at the junction of the apical-lateral membranes (Groschwitz and 
Hogan, 2009). 
1.2 Gastrointestinal complaints in endurance athletes 
 
Gastrointestinal problems are extremely common in endurance athletes and are often reported as 
the main cause of underperformance in a race. Depending on the methodology, 30-90% of 
athletes suffer from gastrointestinal problems during exercise (Jeukendrup et al., 2000).  
However, the mechanisms underlying gastrointestinal symptoms remain unelucidated. 
Symptoms in runners vary greatly from mild exercise related discomfort or nausea to severe pain 
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and diarrhea. Ultimately, these symptoms have the potential to hinder both exercise performance 
and recovery, and disrupt the training progress of an athlete. Currently, there is no standard 
definition of what constitutes a minor or major symptom in this context, but it has been proposed 
that a major symptom is one that affects either health or sports performance (Oliveira et al., 
2014). No sport specific symptom pattern can be found among runners but instead symptoms are 
highly individual. However, gastrointestinal disturbances occur more often during running than 
in sports with less vertical impact (Wright et al., 2011). Gastrointestinal symptoms can usually 
be classified into either upper or lower gastrointestinal symptoms. Typically lower 
gastrointestinal symptoms are more severe and more common in runners but even upper 
gastrointestinal symptoms can be harmful and have severe health consequences (Peters et al., 
1999).  
1.2.1 Prevalence of gastrointestinal complaints  
 
Symptom occurrence varies greatly between different competitions and individuals. In elite 
athletes, the prevalence of gastrointestinal complaints was reportedly 70% (Peters et al., 1999) 
while in an internet-based questionnaire study of 1281 athletes, 45% of runners reported 
gastrointestinal symptoms during running (Steege et al., 2012). A total of 85% of participants at 
an ultramarathon experienced gastric bleeding (Baska et al., 1990) and 93% of triathletes 
competing in difficult conditions experienced gastrointestinal problems such as flatulence, urge 
to defecate, heartburn, abdominal pressure, nausea, stomach ache, intestinal cramps and urge to 
vomit (Jeukendrup et al., 2000). Besides the large variation in prevalence of symptoms seen with 
different methodologies, symptoms also vary largely depending on age, gender, training status, 
environmental conditions and exercise intensity. Often, gastrointestinal symptoms may be 
disruptive enough to cause dropping out of the race. In the study by Jeukendrup et al. (2000), 
14% of the participating athletes were unable to complete the race and in the study by Stuempfle 
and Hoffman (2015), 35.6% of non-finishers in the race dropped out due to gastrointestinal 
distress. Gastrointestinal symptoms also played a major role in the athletes' performance and 
recovery as nearly half of race finishers reported that gastrointestinal symptoms affected their 
race performance (Stuempfle and Hoffman, 2015). The gastrointestinal damage incurred by 
runners may even include mucosal lesions and ischemic colitis which are both commonly 
observed during running (Choi et al., 2001; Gaudin et al., 1990; Steege et al., 2012) along with 
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gastric bleeding (Baska et al., 1990). In the study by Gaudin et al. (1990), all runners showed 
pathological features of gastrointestinal lesions following a 18-50km run. Similarly, in the study 
by Steege et al. (2012), gastrointestinal ischemia was observed in all athletes following 
maximum intensity exercise. Despite the common occurrence of symptoms, the etiology of 
gastrointestinal complaints in endurance athletes remains poorly understood.   
 
1.2.2 Physiological causes of gastrointestinal complaints 
 
Currently it is recognized that while the etiology of exercise-induced gastrointestinal 
disturbances is likely multifactorial, intestinal ischemia and subsequent alterations in epithelial 
membrane permeability are ascribed as the main pathophysiological mechanisms for the 
development of symptoms (Oliveira et al., 2014). Other factors affecting symptom development 
likely include nutritional and mechanical factors along with a possible genetic influence. 
1.2.2.1 Changes in gut motility 
 
Changes in gut motility occur frequently during running and may be observed in the esophagus, 
stomach, or intestine. Studies have linked decreases in sphincter tone to gastro-esophageal reflux 
while the effects on gastric emptying are still less clear (Oliveira et al., 2014). One early finding 
showed no change in gastric emptying at moderate intensity while another showed that high 
intensity or intermittent exercise may reduce gastric emptying time (Oliveira et al., 2014). 
However, other studies have shown that exercising in hot conditions or while dehydrated reduces 
gastric emptying time (Neufer et al., 1989; Rehrer et al., 1990a). Additionally, damage to 
gastrointestinal mucosa increases in very hot or humid conditions while dehydrated due to the 
reduction in blood volume and increased ischemia. Damage to intestinal epithelia in turn can 
lead to more gastrointestinal disturbances. Contrary to the changes in esophageal or gastric 
motility, effects on the small intestine seem to be small. One study examined small intestinal and 
colonic transit time in symptomatic and asymptomatic runners at rest and during exercise but 
failed to see any difference in transit time even though diarrhea was observed in the study (Rao 
et al., 2004). This would indicate that the symptoms were not caused by changes in transit time 
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but by some other mechanism instead. Overall, the effect of exercise on gut motility appears 
quite small although some changes to gastric emptying time occur at higher intensities.  
 
1.2.2.2 Splanchnic hypoperfusion 
1.2.2.2.1 Redistribution of blood flow 
 
Long-duration exercise places an extreme adaptive demand on the body and leads to a 
redistribution of blood flow. During exercise, blood is diverted to the working muscles and 
cardiopulmonary system to supply the higher oxygen and nutrient demands. Norepinephrine is 
released during strenuous exercise in the sympathetic nervous system to trigger splanchnic 
vasoconstriction and allow greater blood flow to active tissues (Wright et al., 2011). Blood is 
also diverted to the skin and periphery to increase heat dissipation and cool the body. This 
demand by the working muscles and active tissues directs blood away from the central tissues 
including the stomach, intestines and liver. As much as 80% of blood flow to the gut is diverted 
in humans during exercise (Clausen, 1977). This decreased splanchnic blood flow leads to 
ischemic damage to the intestinal epithelial cells and disrupts the integrity of the gastrointestinal 
barrier (Pals et al., 1997; Wijck et al., 2012). This disruption of the gastrointestinal barrier may 
be the cause of the reported nausea, vomiting, diarrhea, and pain (Oliveira and Burini, 2009, 
2011) although direct evidence is still lacking. Dysfunction of the epithelial gastrointestinal 
barrier can also affect physical performance and post-exercise recovery negatively by causing 
gastrointestinal distress and impairing uptake of nutrients, fluids, and electrolytes (Oliveira et al., 
2014). Intestinal ischemia is often caused by a combination of hyperthermia, dehydration, and 
exhaustion (Oliveira and Burini, 2009). Further damage to epithelia can also be caused after 
ischemia by reperfusion of blood due to oxidative stress and inflammation (Grootjans et al., 
2010). In an investigation by Schaub et al. (1985), epithelial surface changes known to occur 
during ischemia were observed in an athlete following a marathon. The ischemia also commonly 
causes gastrointestinal bleeding and intestinal infarctions in some cases even require surgery 
(Lucas and Schroy, 1998).  
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1.2.2.2.2 Endotoxemia 
 
Severe disruption of epithelial integrity by strenuous exercise may also lead to leakage of 
bacterial endotoxin into blood circulation, or endotoxemia, causing inflammation (Jeukendrup et 
al., 2000). The disruption of barrier integrity involves disruption of tight junctions that connect 
epithelial cells, either by loss of tight junction proteins or disruption of cytoskeleton of epithelial 
cells. Intestinal ischemia and reperfusion can also lead to Paneth cell apoptosis (Grootjans et al., 
2011). These cells produce and secrete antimicrobial proteins to prevent bacterial translocations 
and inflammation, and are found in the crypts of the intestine. However, damage to Paneth cells 
during exercise has never been examined but exercise-induced ischemia may contribute to 
Paneth cell destruction and thereby loss of gastrointestinal barrier function (Wijck et al., 2012). 
Damage to the intestine is exacerbated through exercising in hot or humid conditions that cause 
increases in fluid loss through sweating and result in decreased plasma volume and dehydration 
that further lowers the blood supply to the intestine (Lambert et al., 2008a). 
 Patients with major trauma, sepsis, or shock exhibit similar changes in blood redistribution as 
can be caused by extreme exercise (Jeukendrup et al., 2000). In these cases, the hypoperfusion of 
the gut causes shock-induced mucosal damage and permits the leakage of gram-negative bacteria 
or their endotoxins such as LPS into blood circulation. Once in circulation, endotoxins lead to 
various symptoms including fever, nausea, shivering, dizziness, gastrointestinal disturbances 
such as diarrhea and vomiting, and eventually sepsis (Brock-Utne, 1988). These symptoms and 
especially gastrointestinal disturbances are commonly experienced by endurance athletes as 
studies point to a symptom prevalence of 30-50% in marathon runners and gastric ischemia has 
been shown to occur frequently even in asymptomatic athletes (Nielsen et al., 1995).The 
occurrence of  ischemia in asymptomatic athletes may imply that symptomatic athletes are more 
susceptible to the effects of exercise induced ischemia. This is supported by the occurrence of the 
same phenomenon with other gastrointestinal disorders, namely irritable bowel syndrome and 
gastro-esophageal reflux disease (Drossman et al., 2002). Exercise-induced ischemic damage to 
the intestines can also induce mucosal erosions and gastrointestinal bleeding in athletes surveyed 
by endoscopy (Øktedalen et al., 1992). Other methods such as fecal occult blood tests have also 
indicated fecal blood loss in otherwise healthy athletes (Bi and Triadafilopoulos, 2003) and an 
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examination of 450 trained endurance athletes in cycling, triathlon, and running revealed running 
to be most strongly associated with gastrointestinal problems (Peters et al., 1999). This may be 
due to the aforementioned ischemic and mechanical stresses imposed by running at a greater 
degree than lesser-impact sports. While gastrointestinal bleeding induced by exercise does not 
usually merit immediate medical attention, it can affect training and performance and lead to 
more serious harm to the athlete. Studies suggest that up to one quarter of athletes may 
experience gastrointestinal bleeding during intense or prolonged exercise (McCabe et al., 1986). 
Gastrointestinal bleeding may also contribute to the commonly occurring anemia or low iron 
and/or ferritin encountered among runners (McMahon et al., 1984). In a study by Stewart et al. 
(Stewart et al., 1984), 20 out of 24 runners surveyed after a race of 10 to 42.2km showed 
increased fecal hemoglobin levels, indicating a very high occurrence of gastrointestinal bleeding 
among runners.  A cause for the variation in perceived symptoms among athletes may simply be 
overreaching of the adaptive capacity of the gastrointestinal tract. Because while exercise 
induced ischemia has been demonstrated to damage intestinal epithelia, there is also evidence of 
adaptive capability to exercise through improved gastrointestinal barrier function and increased 
gastric emptying (Gisolfi, 2000). This might indicate that the intestinal mucosa adapts to better 
withstand the exercise-induced damage or that its recovery capabilities improve after damage is 
already sustained. Indeed, after one study symptomatic athletes reduced their training intensity 
for a few months and, after slowly building up their training, were able to resume exercise at the 
original intensity (Steege et al., 2012). As one adaptation, blood flow to the intestines is 
generally better maintained in trained than untrained subjects (Gisolfi, 2000). Also, results from 
an animal study indicate that the difference in heat tolerance between sedentary and physically fit 
animals is in part attributable to endotoxin leaving the gut (Gisolfi, 2000). In the study, the rise in 
core temperature during exercise in untrained animals was significantly greater than in trained 
animals. However, injection of indomethacin which blocks endotoxin-induced fever lowered the 
core temperature of the untrained animals to the level of the trained animals (Gisolfi, 2000). 
Additionally, the gastrointestinal system has a capacity to regenerate, with epithelial cells having 
an average lifespan of only four to five days (Gisolfi, 2000). Even in cases where gastric 
bleeding occurs, it is generally no longer detected by esophagogastroduodenoscopy and 
colonoscopy more than 48 hours after exercise (Schwartz et al., 1990). 
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1.2.2.3 Intestinal permeability and absorption 
 
Related to the splanchnic hypoperfusion and subsequent damage to intestinal epithelia is the 
increase in intestinal permeability. Gastrointestinal symptoms during distance running have been 
previously associated with changes to the small intestinal permeability (Øktedalen et al., 1992). 
A vital function of the intestinal barrier is to prevent the penetration of carcinogenic, toxic, or 
antigenic substances into the interstitial fluid and systemic circulation. Entry of pathogens 
through a damaged epithelial barrier with increased permeability provokes a systemic 
inflammatory response that may lead to the gastrointestinal symptoms experienced during 
running (Øktedalen et al., 1992). As mentioned earlier in the review of the gastrointestinal barrier 
function, particles can cross the epithelial barrier through either transcellular or paracellular 
transport. Tight junctions function mainly in paracellular transport but also maintain cell 
polarization in epithelial cells and thus affect transcellular transport. Damage to and loosening of 
tight junctions caused by medications, stress, exercise (Hollander, 1992), disease, alcohol 
(Napolitano, 1995),  or thermal stress (Napolitano, 1995) leads to increased permeability of the 
gut to larger particles. Pals and coworkers (1997) were the first to demonstrate increased 
intestinal permeability at high intensity exercise but no changes at lower intensity. In their study, 
six healthy test subjects experienced significant increases in intestinal permeability following a 
60 minute treadmill run at 80% of maximal oxygen uptake (peak VO2) compared to 40% or 60% 
peak VO2 (Pals et al., 1997). This indicates that permeability changes during exercise may be 
intensity dependent. Moses (1991) also observed increased intestinal permeability during high 
intensity running with subjects running for 90 minutes at 60 and 85% maximal O2 uptake with 30 
second sprints every 15 minutes. Likewise, Oktedalen et al. (1992) demonstrated increased 
permeability after a half-marathon or marathon race. Although the link of increased intestinal 
permeability to gastrointestinal symptoms has not been proven, van Nieuwenhoven et al. (2003) 
demonstrated that symptomatic athletes have increased intestinal permeability following running 
or cycling compared to asymptomatic controls. In the study, intestinal permeability, orocaecal 
transit time, gastric reflux, gastric emptying and glucose absorption were measured in 10 
symptomatic and 10 asymptomatic runners at rest and following running or biking. No 
significant differences were found between the groups during rest. No difference was found in 
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gastric emptying or intestinal glucose absorption either, but orocaecal transit time, gastric reflux, 
and intestinal permeability increased significantly more after exercise in symptomatic runners 
(Nieuwenhoven et al., 2003).  
In summary, exercise can affect the gastrointestinal tract in various ways, many of which are 
intensity dependent. Intense or long-duration exercise can reduce gastric emptying time, cause 
ischemic damage via reduction of blood flow to the intestine, and increase intestinal 
permeability.  
1.2.3 Mechanical causes 
 
Another issue to consider regarding gastrointestinal symptoms in endurance athletes is 
mechanical damage that is related mainly to impact or posture during sports. In a study 
measuring gastroesophageal reflux during cycling or running, running caused significantly 
longer gastroesophageal reflux episodes than biking along with reported heartburn and chest pain 
in some athletes (Peters et al., 2000). This could likely be because of the repetitive impact caused 
by running that could subsequently damage the intestinal epithelia and generate the symptoms. 
The high percentage of blood loss to feces in triathletes following intense training, pre-race, and 
post-race measurements as well as a significant relationship between athlete blood hemoglobin 
level and training run intensity in regression analysis (Rudzki et al., 1995) supports this 
hypothesis of mechanical damage as mucosal damage would lead to gastrointestinal bleeding. In 
20 triathletes, 80% exhibited exercise intensity dependent blood loss to feces (Rudzki et al., 
1995). This intestinal bleeding is likely caused by the combination of mechanical jostling of the 
intestines and the exercise-induced gut ischemia (Moses, 1991; Oliveira and Burini, 2009). A 
lower incidence of gastrointestinal bleeding in cyclists and the absence of blood in feces of 
walkers support the theory that mechanical trauma in runners contributes to occult blood loss 
(Oliveira and Burini, 2009). The bouncing of the intestines may also contribute to other 
symptoms commonly observed in runners, including diarrhea, pain, and urgency (Keeffe et al., 
1984). In a study performed on triathletes by Rehrer et al. (1992), all gastrointestinal symptoms 
reported were found to be more prevalent during the run portion of the triathlon which again may 
stem from the higher impact and mechanical pressure to the gut.  Additionally, posture may play 
a role in the development of specific symptoms. While lower gastrointestinal symptoms are more 
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prevalent in runners, cyclists often experience more upper gastrointestinal disturbances (Peters et 
al., 1999). This may be caused by cyclists bending over the bike handlebars, thus creating 
increased abdominal pressure (Peters et al., 1999). Intake of fluids during exercise can also lead 
to “swallowing of air” that can trigger gastrointestinal symptoms. However, it appears that 
higher levels of training may decrease these gastrointestinal symptoms (Waterman and Kapur, 
2012).  
 
1.2.4 Nutritional causes 
1.2.4.1 Fluids 
 
Nutrient and fluid ingestion before, during, and after running plays an important role in an 
athlete’s performance and training progression. Poorly timed or insufficient nutrition and fluids 
can cause underperformance and impair recovery (Peters et al., 2012). Similarly, certain foods or 
nutrients such as greasy foods, protein, fructose, and fiber have been linked to increased 
gastrointestinal distress while running (Rehrer et al., 1992). For example, gastrointestinal 
symptoms reported by triathlon participants were associated with certain nutritional factors 
including ingestion of fat, protein, fiber, or concentrated carbohydrate drinks (Rehrer et al., 
1992). Particularly osmolalities greater than 500 mOsm/L were found to cause gastrointestinal 
distress (Rehrer et al., 1992). It appears that foods or drinks that draw fluid into the intestines 
may be a major cause of some gastrointestinal symptoms. The concentrated carbohydrate drinks 
are one example of such substances that can cause fluid accumulation. The effects of 
carbohydrate intake on gastrointestinal symptoms overall are still less clear. In a study by 
Pfeiffer et al. (2009) conducted on 26 men and 8 women, high carbohydrate (CHO) intakes of 
1.4g CHO per minute compared to moderate intake of 1.0g CHO per minute did not produce any 
increase in gastrointestinal symptoms during a 16km run and both were well tolerated. In a 
second branch of the randomized double-blind study, 34 men and 14 women were allocated to 
receive either a glucose or glucose + fructose gel providing 1.4g CHO per minute. Again, no 
difference was found between groups indicating that the composition of the carbohydrate blend 
did not play a role in the development of gastrointestinal symptoms (Pfeiffer et al., 2009). 
However, in a study by Wallis et al. (2007) performed on 8 endurance-trained women, increasing 
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carbohydrate consumed during cycling led to an increase in gastrointestinal symptoms. In this 
study the sample size was not large enough to perform statistical analyses on gastrointestinal 
symptom reports so the results must be taken as descriptive only. The study used water and three 
different glucose concentrations (0.5g/min, 1.0g/min, 1.5g/min) to test effects on glucose 
oxidation and endogenous glucose sparing and included a questionnaire on gastrointestinal 
symptoms (Wallis et al., 2007). Although the greatest symptom occurrence was reported at the 
high concentration of 1.5g glucose per minute, the highest rate of glucose oxidation and greatest 
endogenous glucose sparing occurred at the moderate level of 1.0g per minute carbohydrate 
indicating a race performance advantage at this level of ingestion (Wallis et al., 2007). In a larger 
study performed on 221 endurance athletes, higher carbohydrate intakes during competition were 
associated with increased nausea and flatulence, but also with decreased race finish time (Pfeiffer 
et al., 2012). This indicates that while higher rates of carbohydrate intake may be associated to 
certain gastrointestinal symptoms, they also contribute to faster finishing times and improved 
performance. Considering the faster finishing times, the nausea caused by ingestion of gels was 
likely not severe. From these studies it may be postulated that carbohydrate intake itself is not 
necessarily the cause of gastrointestinal symptoms but that the response may vary depending on 
the concentration or osmolality of the gel or beverage (Oliveira et al., 2014). 
Another important factor in running performance is fluid ingestion and especially avoiding 
dehydration. There appears to be link between dehydration during exercise and subsequent 
gastrointestinal distress. In a field study conducted on 44 runners participating in a marathon, 
body weight losses of about 4-5% were associated with increased incidence of gastrointestinal 
disorders (Rehrer et al., 1989). Of runners who lost more than 4% of their body weight, 80% 
experienced gastrointestinal disturbances which likely were caused by a combination of factors 
including fluid loss, intestinal ischemia, and elevated core body temperature (Rehrer et al., 
1989). Further studies by Rehrer et al. (Rehrer et al., 1989, 1990b) in the laboratory 
demonstrated that ingestion of fluids during rest, running or biking did not cause any 
gastrointestinal symptoms. The discrepancy between symptom reports during races and the 
laboratory findings may be explained by the fact that those reporting symptoms after drinking are 
likely already dehydrated as it has been demonstrated that voluntary consumption of fluids 
during exercise is not enough to prevent dehydration (Kristal-Boneh et al., 1988; Strydom et al., 
1966).  Another factor may be experience level in the use of fluids during practice runs. If one 
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has trained the intake of fluids during practices then symptoms during competition are less likely 
to occur (Lambert et al., 2008b). Perhaps the exercise intensity during races is also higher than in 
training or the psychological stress of a race may affect the development of gastrointestinal 
symptoms.  
 
1.2.4.2 Carbohydrate and fats 
 
Since carbohydrate consumption and hydration has been shown to benefit performance, it has 
been postulated that the gut may adapt to allow the ingestion of fluids and carbohydrate during 
exercise (Oliveira et al., 2014). It has been shown that athletes not accustomed to ingesting foods 
and fluids during exercise have a twofold increase in the risk of developing gastrointestinal 
symptoms during exercise (Steege et al., 2008). Cox et al. (2010) demonstrated that the gut can 
be trained to adapt to increased carbohydrate consumption during exercise. In their study, 16 
triathletes or cyclists were pair matched and randomly assigned to iso-energetic groups of either 
high carbohydrate or low carbohydrate content for 28 days. After 28 days, exogenous glucose 
oxidation rates were significantly higher in the high carbohydrate group, indicating adaptation to 
the carbohydrate ingested during training. However, this increase in glucose oxidation did not 
translate to increases in training-induced improvements in exercise performance (Cox et al., 
2010). Lambert et al. (2008b) assessed adaptation to fluids with repeated sessions of fluid 
ingestion during running. A total of seven endurance-trained subjects participated in six 90 
minute treadmill running trials while drinking a glucose-electrolyte solution. In the first trial 
subjects drank ad libitum and in subsequent trials subjects were given fluid according to the rate 
of fluid loss in sweat determined during the first trial. Gastrointestinal symptoms decreased 
during repeated trials even though gastric emptying rate did not change (Lambert et al., 2008b). 
Thus, studies suggest that the gastrointestinal system can adapt to fluid and food intake during 
exercise but more studies are warranted to investigate the extent and mechanisms underlying 
such adaptations. 
In addition to fluid and carbohydrate intake, other diet components affect intestinal permeability 
(Kelly et al., 2015) although their role in causing gastrointestinal symptoms during exercise is 
not well established. Especially high-fat diets have been implicated with increased translocation 
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of LPS across the gut wall (Moreira et al., 2012). High fat diets increase plasma and fecal 
endotoxin and lead to reduced expression of the tight junction proteins claudin-1 and occludin 
(Kim et al., 2012). Foods high in fiber and vegetables have been shown to decrease the high fat 
or high carbohydrate induced increase in LPS translocation (Ghanim et al., 2009). However, 
fiber has also been linked to increased gastrointestinal symptoms in athletes (Rehrer et al., 1992).  
1.2.4.3 Probiotics 
 
Probiotics and prebiotics have also been shown to affect intestinal permeability. In a double-
blinded placebo-controlled cross-over study, lactobacilli probiotics were administered for six 
weeks to children with moderate and severe atopic dermatitis (Rosenfeldt et al., 2004). The 
probiotic supplementation significantly decreased gastrointestinal symptoms in the children and 
resulted in stabilization of the intestinal barrier function (Rosenfeldt et al., 2004). In another 
study, lactobacilli probiotics administered to healthy adults significantly increased zonula 
occludens (ZO)-1 and transmembrane protein occludin in the vicinity of the tight-junctions 
(Karczewski et al., 2010). In the in vitro arm of the study, probiotics induced translocation of 
zonula occludens to the tight junctions in human epithelium. Additionally, in a randomized 
double-blind placebo-controlled study, 14 weeks of multi-species probiotic supplementation in 
athletes decreased fecal zonulin following intense exercise compared to controls when measured 
at baseline and after 14 weeks (Lamprecht et al., 2012). Zonulin is a protein known to reversibly 
regulate intestinal permeability by modulating intercellular tight junctions (Fasano, 2011). It can 
be used as a biomarker of impaired gut barrier function (Fasano, 2012). Some environmental 
stimuli such as intestinal exposure to bacteria or to gluten lead to zonulin release (Fasano, 2011). 
Zonulin-dependent loss of barrier integrity is also implicated in a number of autoimmune 
diseases including celiac disease (Fasano, 2009) and type I diabetes (Fasano, 2012; Sapone et al., 
2006). Thus, the reduction in fecal zonulin after probiotic supplementation indicates improved 
gastrointestinal barrier integrity.   
1.2.5 Non-Steroidal Anti-Inflammatory medications 
 
In addition to nutritional causes, gastrointestinal disturbances may arise from the use of non-
steroidal anti-inflammatory medications (NSAIDs). In a questionnaire based study, a large 
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number of athletes reported using NSAIDs before or during races either for treatment of injuries 
or for anticipated pain reduction (Gorski et al., 2011). However, they were mostly unaware of 
any adverse effects, which were thoroughly investigated by Gabriel et al. (1991) and included a 
three times greater relative risk for developing severe adverse gastrointestinal events such as 
mucosal bleeding or perforation. A study conducted on the Chicago marathon runners 
investigated the effects of ibuprofen and aspirin ingestion during prolonged exercise and found 
that Ibuprofen was associated with increased intestinal permeability and gastrointestinal 
symptoms (Smetanka et al., 1999). Similar results were found by Van Wijck et al. (2012) who 
studied the effects of ibuprofen intake during cycling. Ibuprofen consumption resulted in 
increased plasma intestinal fatty acid binding protein (I-FABP) which was used to measure the 
degree of small intestinal damage. Consequently, small intestinal permeability also increased 
with ibuprofen ingestion and the extent of small intestinal injury and barrier disruption correlated 
significantly (Van Wijck et al., 2012). Thus, the use of NSAIDs in athletes is strongly 
discouraged.   
1.3 Exercise related endotoxemia 
1.3.1 Endotoxemia mechanism 
 
Ischemic damage, mechanical trauma, and heat stress can all lead to damaging of the intestinal 
endothelial cells and breakdown of the gastrointestinal protective barrier (Gisolfi, 2000). This 
allows gram-negative bacteria and their endotoxins such as LPS to penetrate through the 
loosened tight junctions and enter the blood circulation and lymph nodes (Jeukendrup et al., 
2000), overwhelming the ability of the liver to clear the endotoxin via the reticulo-endothelial 
system. The symptoms often experienced by runners including nausea, vomiting, dizziness, high 
body temperature, and even renal failure are very similar to those provoked by LPS (Jeukendrup 
et al., 2000). Endotoxins trigger the host’s immune response via incitation of the cytokine 
network (Jeukendrup et al., 2000). The central inflammatory mediator is proposed to be TNF-α 
which is produced by both macrophages and monocytes (Jeukendrup et al., 2000). The role of 
TNF-α is to stimulate production of other cytokines by monocytes or other cells such as 
endothelial cells. TNF-α also participates in triggering of the acute-phase response along with the 
other inflammatory cytokines interleukin-1 (IL-1) and interleukin-2 (IL-6) (Deventer et al., 
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1990). The acute phase response provoked involves profound changes in plasma protein 
concentrations that prepare the body for defense against harm such as an inflammatory agent or 
wound (Jeukendrup et al., 2000).  
1.3.2 Endotoxemia and LPS following strenuous exercise 
 
Endotoxemia has been reported in some studies after strenuous exercise although the findings are 
not consistent. In a study by Brock-Utne et al. (1988) the plasma increase in endotoxin levels 
was measured in randomly selected participants in an ultramarathon event. A total of 89 subjects 
were selected from runners entering the medical tent and 81% of the study participants had 
elevated LPS endotoxin levels (above 0.1 ng/ml) with 2% over the reported lethal limit in 
humans (1ng/ml) (Brock-Utne, 1988). Additionally, runners completing the race in less than 
eight hours had significantly lower mean plasma endotoxin levels than those taking over eight 
hours (Brock-Utne, 1988). This may be due to longer duration of mechanical, ischemic and heat 
damage to intestine in those runners taking more time to finish the race, ultimately causing a 
greater disruption in intestinal barrier regulation (Brock-Utne, 1988). Of the runners with high 
endotoxin levels (0,329 ± 0,026 ng/ml), 80.6% experienced gastrointestinal symptoms including 
vomiting, diarrhea and nausea while only 17.7% of those with low endotoxin levels (0,075 ± 
0,005 ng/ml) experienced symptoms (Brock-Utne, 1988). These findings indicate that increased 
intestinal permeability and subsequent endotoxemia may be contributing to the high 
gastrointestinal symptom prevalence among runners. Interestingly, plasma endotoxin 
concentrations and anti-endotoxin IgG concentrations showed a negative correlation (Brock-
Utne, 1988). High endotoxin concentrations in the study fell back to normal range after 1-3 
weeks in 32 randomly selected runners with endotoxemia and anti-LPS levels were significantly 
higher than immediately after the run (Brock-Utne, 1988). Conversely, no increases in endotoxin 
concentrations were found in runners participating in a shorter half-marathon event but anti-
endotoxin IgG levels were higher than in those completing the ultramarathon, possibly because 
of previous exposure and development of antibodies following a marathon three weeks before 
the measurements (Brock-Utne, 1988). The lack of plasma endotoxin concentration increases 
could also be caused by less exhaustion in the shorter event, or perhaps by cooler temperatures 
(Brock-Utne, 1988). Similar results were obtained in a study by Bosenberg et al. (1988) where 
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endotoxin and anti-endotoxin IgG concentrations were tested before and after an ultradistance 
triathlon. As in the study performed by Brock-Utne et al. (1988) plasma LPS levels showed 
significant increase following the race whereas plasma anti-LPS IgG levels decreased 
significantly (Bosenberg et al., 1988). Interestingly, both LPS and anti-LPS IgG concentrations 
were directly related to the subject’s training intensity (Bosenberg et al., 1988). It is possible that 
training-induced damage to the epithelium leads to leakage of endotoxin into circulation and 
allows the formation of anti-LPS antibodies, possibly attenuating symptoms (Bosenberg et al., 
1988). Thus, LPS leakage from the intestine to blood circulation during a race would be 
attenuated by greater numbers of anti-LPS binding in trained subjects. In a recent study, 
endotoxin and C-reactive protein (CRP) concentrations increased in ultra-endurance runners 
compared to controls during a race (Gill et al., 2015). Gastrointestinal symptoms were reported 
in 75% of Ultra-endurance runners with no symptoms reported in the controls.  
However, contrasting studies to those linking increased permeability and bacterial translocation 
to exercise induced gastrointestinal symptoms exist. Moore et al. (1995) investigated whether 
endotoxemia was linked to exercise-associated collapse in cyclists participating in a 100-mile 
race but found no significant difference in endotoxin concentrations between symptomatic 
athletes and controls. It may be that the bike ride was not strenuous enough to produce the same 
level of damage to intestinal epithelia as an ultradistance run or triathlon (Moore et al., 1995). In 
addition, a study by Camus et al. (1997) conducted on marathon participants found a moderate 
and transient increase in endotoxin levels and slight decrease in anti-endotoxin IgG levels but 
could not establish a correlation between either of these factors and the observed increase in 
inflammatory cytokines such as TNF-α and interleukin 6 (IL-6). However, the study authors 
agree that the measurement of LPS may not have been inclusive enough to show the true amount 
of bacterial translocation occurring during the marathon or later during the recovery period as 
measurements were made at 0 h, 1 h, and 24 h post race (Camus et al., 1997). Another factor 
contributing to this under-evaluation could be the binding of endotoxin to ligands, such as CD14 
receptors, and LPS-binding protein (Camus et al., 1997). The authors also agree that further 
studies about the effect of increased permeability and bacterial translocation, and exercise 
induced symptoms are warranted (Camus et al., 1997). 
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1.3.3 Inflammatory cytokines 
 
Another marker of endotoxin leakage is anti-LPS IgG for which a change may be easier to detect 
as the potential decrease in the amount of antibodies occurs over a longer period of time than the 
transient increase in LPS concentration which may be difficult to measure (Jeukendrup et al., 
2000). The persistence of the antibody decrease occurs due to formation and clearance of LPS-
anti-LPS complexes (Jeukendrup et al., 2000). Additionally, decreases in anti-LPS levels can 
also be seen in the systemic circulation even when LPS concentration increase only occurs in the 
intestine or portal circulation (Jeukendrup et al., 2000). This marker of endotoxin leakage was 
used by Jeukendrup et al. (2000) who measured anti-LPS IgG, LPS, and inflammatory cytokines. 
In total, 93% of study participants reported gastrointestinal symptoms and a mild increase in LPS 
concentration and a corresponding decrease in anti-LPS concentration was detected following 
the race (Jeukendrup et al., 2000). Additionally, 40% lower anti-LPS IgG concentrations were 
detected in trained subjects than in untrained controls, supporting the findings of previous studies 
and indicating leakage of endotoxin and subsequent antibody production during training 
(Jeukendrup et al., 2000). The increased level of anti-LPS antibodies can then bind plasma LPS 
after damage to intestinal barrier and possibly minimize development of gastrointestinal 
symptoms. Measures of inflammatory cytokines revealed no increase in TNF-α, contrary to the 
study by Camus et al. (1997). However, the finding is not surprising when taking into account 
that TNF-α was detected in only 5-54% of patients with sepsis in various studies (Hack et al., 
1997). This may be because of the rapid clearance time of TNF-α and perhaps the sensitivity of 
assays in use at that time. Increased IL-6 levels were, however, reported in the study by 
Jeukendrup et al. (2000). This points to connection with increased endotoxin concentrations as 
LPS can stimulate the production of pro-inflammatory cytokines including IL-6, TNF-α, and 
CRP (de Punder and Pruimboom, 2015). However, increased IL-6 could also be a product of 
muscle damage or the exercise itself as Bruunsgaard et al. (1997) demonstrated that IL-6 
concentrations increased significantly after 2 h of eccentric exercise and that the IL-6 
concentration was significantly correlated with the creatinine kinase concentration as a parameter 
of muscle damage. The levels of positive acute-phase reaction protein CRP were also found to 
increase 20-fold 16 hours post-race (Bruunsgaard et al., 1997). This is in agreement with other 
studies including Dufaux et al. (1984) and Liesen et al. (1977) where CRP levels were measured 
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the day after two hour or three hour run respectively, and showed a six-fold increase. Liesen et 
al. (1977) also demonstrated decreased acute-phase response and CRP in trained individuals. 
Fecal calprotectin can also be used for assessment of intestinal damage. Calprotectin can inhibit 
zinc-dependent enzymes which are needed to activate cytokines like TNF-α and as such 
participate in the destruction of microbes (Steinbakk et al., 1990). However large concentrations 
of the protein may induce cell and tissue damage (Aadland and Fagerhol, 2002). Calprotectin has 
been shown in many studies to act as a reliable marker of inflammation or damage to the 
gastrointestinal tract (Aadland and Fagerhol, 2002).  In a study by van Wijk et al. (2011), 
significantly increased fecal calprotectin levels were found after subjecting healthy males to 60-
minutes of moderate to high intensity exercise along with increases in small intestinal 
permeability and small intestinal injury. Figure 3 (p.25) provides a summary of the effects of 
exercise-induced endotoxemia on intestinal permeability changes.  
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Figure 3. Schematic diagram illustrating proposed mechanisms of increased intestinal permeability and gut-barrier 
impairment caused by exercise. Mechanisms with experimental evidence are capitalized. Exercise, especially in 
combination with heat, dehydration, or NSAIDs increases core body temperature. Splanchnic vasoconstriction 
occurs to make more blood available to exercising muscles but splanchnic ischemia, cellular hypoxia, and nitric 
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oxide (NO•) production cause biochemical effects that can lead to increased intestinal permeability. The increased 
permeability leads to secretion of interferon-γ (INF-γ), which further reduces gut-barrier function. Constitutive NO• 
may protect intestinal barrier function by inhibition of inflammatory cells or neutralization of reactive oxygen 
species. However, large amounts of NO• lead to reduced gut-barrier function and to endotoxin leak, production of 
inflammatory mediators, hypotension, and circulatory shock/heat stroke. Heat shock protein (HSP) production in 
response to high core body temperature can attenuate effects of NO• (Gisolfi, 2000).  
 
1.4 Measuring intestinal permeability 
 
Intestinal permeability is a measure of intestinal barrier function and relates to the paracellular 
space between neighboring enterocytes and their adhesive junctional complexes (Turner, 2009). 
Intestinal permeability can be measured by passive movement of different-sized molecules 
across the gastrointestinal epithelial barrier. Among the most commonly used molecules are 
mono- and disaccharide probes, chromium-labeled Ethylenediaminetetraacetic acid (EDTA), and 
different weight polyethylene glycols (PEGs). The use of oligosaccharides for measuring 
intestinal permeability was introduced by Menzies and marked the creation of the principle of 
differential urinary excretion of orally administered probes which is commonly used for the 
measurement of intestinal permeability (Menzies, 1974). Intestinal permeability is measured in 
vivo via these non-invasive test substances. Initially, single test substances such as lactulose, Cr-
EDTA, technetium-labeled diethylenetriaminopentaacetare (Tc-DTPA), and PEG were used but 
results of the permeability studies were influenced not only by permeability changes but also any 
other pre- or post-mucosal changes (Bjarnason et al., 1995). This led to the use of differential 
urinary excretion of test substances, the most common of which is the use of a di- and 
monosaccharide (Bjarnason et al., 1995).  An ideal permeability probe is one that is water 
soluble, shows first order kinetics, is nondegradable, nontoxic, and not metabolized in the 
intestine (Bjarnason et al., 1995). The probe should also not be present naturally in urine or in 
circulation if measured from plasma (Bjarnason et al., 1995).  
1.4.1 Factors affecting permeability measurements 
 
Hyperosmolar stress is one factor that can affect the permeability of the small intestine and 
potentially lead to the development of gastrointestinal symptoms. For example, administration of 
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hypertonic lactulose will lead to increased permeability (Laker and Menzies, 1977). An increase 
in sucrosuria was shown early on after increasing concentration of sucrose administered to 
subjects and later increased permeation of the oligosaccharide probe lactulose was demonstrated 
when osmolarity of test substance is increased beyond 1500 mOsm/L (Laker and Menzies, 1977; 
Menzies, 1974). Osmotic fluid retention of poorly permeating solutes also leads to faster 
intestinal transit times which reduce sensitivity of measurements.  
Another factor that must be considered is the pathway the probes take during permeation. Based 
on their physiochemical properties, it might be expected that the probes have similar modes of 
passage across the epithelial barrier but results showing consistent differences between the 
probes challenge that idea (Bjarnason et al., 1995). Indeed, three different pathways of action 
were proposed based on work by Maxton et al. (1986) where healthy volunteers were given a test 
solution of iso-osmotic, hyperosmotic, or cetrimide containing PEG 400, lactulose, L-rhamnose, 
and Cr-EDTA. Cetrimide was used as a detergent to disrupt the intestinal barrier. Urinary 
recovery of the probes was measured and findings showed low intestinal permeation of ingested 
lactulose and Cr-EDTA but 45-fold permeation of L-rhamnose and 100-fold permeation of PEG 
400, compared to lactulose (Maxton et al., 1986). Passage of lactulose and Cr-EDTA was 
substancially increased by cetrimide and hyperosmolar stress, while permeation of L-rhamnose 
showed little change. PEG 400 was not affected by cetrimide, but the permeability was slightly 
increased by hyperosmolar stress (Maxton et al., 1986). Based on these findings and as shown in 
the three-pathway model in Figure 4 (p.28), Cr-EDTA and lactulose were described as using the 
paracellular mode of transport while rhamnose also permeates via the transcellular pathway 
through pores and PEG 400 via transcellular pathway and lipid membranes (Bjarnason et al., 
1995).  
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Figure 4. The three-pathway model for intestinal permeability predicts that lactulose and Cr-EDTA diffuse through 
the paracellular route across tight junctions while rhamnose and PEG 400 also utilize the trancellular pathway via 
pores and lipid membranes respectively (Bjarnason et al., 1995).  
The three-pathway proposal explains quite well the behavior of the probes but some points of 
contention remain. For one, the direct evidence for these pathways is still lacking because most 
localizing techniques require binding of the markers to cell components which permeability 
probes lack. Also, the permeation of monosaccharides is still controversial as, for example, 
mannitol is used to osmotically shrink membrane vesicles, a feat which would not be possible if 
its permeability was unrestricted (Kessler et al., 1978). An alternative to these proposed 
pathways is the single paracellular model shown in Figure 5 (p.29) whereby all of the probes 
utilize the paracellular pathway. The differences in permeation rates are then explained by 
differences in rates of passage based on the tightness of junctions and the accessibility of probes 
to the crypts (Bjarnason et al., 1995).   
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Figure 5. The single paracellular pathway model predicts that 
lactulose, Cr-EDTA, rhamnose, and PEG 400 all permeate through 
the paracellular route between epithelial cells according to the 
regional permeability characteristics. It is suggested that junction 
tightness increases toward the villus tips. Only the PEG 400 and 
rhamnose would pass through these tighter tight junctions while 
closer to the crypt also lactulose and Cr-EDTA would be able to pass 
(Bjarnason et al., 1995).  
 
 
 
1.4.2 Mono- and disaccharide probes 
 
Mono- and disaccharide probes have been widely used in the measurement of intestinal 
permeability by assessing their recovery from either urine or blood. The most common sugar 
probe is lactulose but other suitable probes include rhamnose, melibiose, raffinose, stachyose and 
dextrans (Bjarnason et al., 1995). These sugars cover many of the “ideal” probe characteristics 
but consideration must be paid to analytical procedures and their accuracy, precision, sensitivity, 
and resolution. The dose of oligosaccharide probe administered should also not exceed five 
grams as poorly permeating solutes retain fluid in the intestine and decrease the transit time, 
leading to less contact between the probes and intestinal wall (Bjarnason et al., 1995). Some of 
the probe sugars may also be found in common food items, which must be taken into 
consideration (Bjarnason et al., 1995).  
Monosaccharides commonly used for the measurement of intestinal permeability are rhamnose 
and mannitol. The urinary excretion of rhamnose 24 hours after intravenous administration is 
incomplete but mannitol excretion was found to be complete (Laker et al., 1982). However, 
small amounts of mannitol is naturally present in urine but should be negligible with 1g mannitol 
administration (Laker et al., 1982). The lactulose-to-rhamnose ratio had been used in patients 
with Crohn´s disease (Howden, 1991), cystic fibrosis (Leclercq-Foucart, 1987), and celiac 
disease (Greco et al., 1991) and it has been demonstrated to correlate with excretion of 
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chromium-labeled EDTA (Maxton et al., 1986). The inclusion of rhamnose improves the 
discriminatory power of the probe since factors that affect transit and excretion affect both 
lactulose and rhamnose equally. Thus, the lactulose-to-rhamnose ratio is preferred instead of a 
single oligosaccharide probe for permeability measurements (Meddings, 1997). Lactulose-
mannitol ratio is another commonly used probe that functions based on the same principle as 
lactulose-rhamnose. Cellobiose and mannitol have also been used together to minimize external 
factors (Cobden et al., 1985). 
Sucrose is sometimes used as a method of determining gastric permeability. In theory, sucrose 
reaching the small intestine should be digested completely and thus any sucrose collected in 
urine would serve as a marker of damage to gastric mucosa (Bjarnason et al., 1995).  
1.4.3 Cr-EDTA and Tc-DTPA 
 
Cr-EDTA and Tc-DTPA function very similarly to oligosaccharide probes but have the added 
benefit of easier detection based on radioactivity. However, the radioactivity is also a major 
disadvantage of the probes. The radiation dose from Cr-EDTA is <0.12 milliSieverts and even 
less for an equivalent dose of Tc-DTPA (Bjarnason et al., 1995). Both probes are often used for 
measuring glomerular filtration rates. The probes are administered in water orally after an 
overnight fast and urine is collected for 24 hours similarly to oligosaccharide probes, as the 
distinction between patients with small intestinal abnormalities and controls is greatest at that 
time (Bjarnason et al., 1983). However, a 5 hour urinary recovery can be used together with a 
monosaccharide probe to increase specificity and simply interpretation of results (Bjarnason et 
al., 1989) although a possible disadvantage is that Cr-EDTA is not degraded and may lead to 
bacterial overgrowth that can influence the urinary excretion ratio and decrease intestinal transit 
time without actual increase in permeability (Bjarnason et al., 1995). However, the non-
degradation allows Cr-EDTA to be used as a marker of both small intestinal and large intestinal 
permeability. Usually the choice between the two probes comes down to ease of handling as due 
to differences in half-life, Cr-EDTA can be made in batches but Tc-DTPA must be made 
individually and be analyzed rapidly after collection (Bjarnason et al., 1995).  
31 
 
1.4.4 Polyethylene glycols 
 
Polyethylene glycols (PEGs) have a general formula of H(OCH2CH2)nOH. Most commercially 
used permeability probes (PEG 400,600,900, 1000, 3000, and 4000) are sold as mixtures of 
different molecular weight polymers. Although polyethylene glycol 400 is used in permeability 
studies, its use in permeability measurements has encountered some criticism because of the 
great variability in demonstrated urinary recovery rates and low recovery after intravenous 
administration (Bjarnason, 1994). PEGs are also commonly used as food additives, solvents, 
toothpaste, and as a water-soluble base for ointments (Bjarnason et al., 1995). PEG 6000 at high 
concentrations facilitates cell membrane fusion and is toxic to cells (Aldwinckle et al., 1982). 
Although the safety margin of PEGs is wide, there is a considerable amount of variation in 
toxicity between different polymers (Bjarnason et al., 1995). The most common PEG used in 
permeability studies is PEG 400 of which 5-10g is usually administered orally and urine is 
collected for 5-6 hours thereafter. The polymers are then isolated from urine samples and 
quantified by gas or high pressure liquid chromatography (Bjarnason et al., 1995).  However, the 
lack of consensus on expression of PEG data results makes interpretation of results difficult 
despite common use in permeability studies (Chadwick et al., 1977; Kerckhoffs et al., 2010; 
Parlesak et al., 1994; van Wijck et al., 2012).   
1.4.5 Iohexol 
 
Iohexol is a water-soluble contrast agent that partially permeates through the small intestinal wall 
and is excreted unchanged in urine. It has been used for small bowel examinations and intestinal 
perforation when administered orally (Aakhus, 1983). Studies in rats have shown that iohexol 
can be used to differentiate between strangulation and obstruction because increased urinary 
excretion of iohexol occurs from an ischemic small intestine (Stordahl, 1988). Excretion of 
iohexol was also increased in rats with selective irradiation of the small intestine (Solheim et al., 
1991). These investigations indicated that iohexol was absorbed and excreted unchanged and that 
the urinary recovery of iohexol reflects damage to small intestine. Halme et al. (1993) showed 
that iohexol can be used in Crohn’s disease patients to determine severity of intestinal 
inflammation. In that study, permeation of iohexol in patients was significantly higher than in 
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controls (Halme et al., 1993). A previous study showed iohexol permeation in intact baby and 
neonatal mucosa to be very low (less than 1% of enterally administered dose) (Langer et al., 
1987). Halme et al. (1993) also determined that while serum iohexol does not produce a reliable 
result, oral iohexol urinary excretion can be used effectively and that body weight shows no 
correlation to excretion of iohexol. The same dose can thus be used for each test subject. The 
results also suggested that iohexol has a better correlation with C-reactive protein (CRP), clinical 
activity index, and endoscopic findings in Crohn’s patients than previous test probes and that 
mucosal damage or inflammation is strongly indicated with urinary excretion of over 0.5% 
iohexol (Halme et al., 1993). In a second study, Halme et al. (1997) investigated the use of 
iohexol as a marker of disease activity in inflammatory bowel disease patients. The results again 
showed significant increase in urinary excretion of iohexol in active disease patients compared to 
controls. Halme et al. (2000) also compared the use of iohexol to the use of lactulose-mannitol 
ratio which is a more commonly used permeability marker in inflammatory bowel disease. The 
correlation between urinary excretion of iohexol and lactulose-mannitol ratio in the study was 
positive and urinary excretion of iohexol correlated positively with endoscopic disease activity 
and modified Harvey-Bradshaw index which measures disease activity index in Crohn’s disease 
patients. In contrast, the lactulose-mannitol ratio only correlated positively with endoscopic 
disease activity but not the clinical index (Halme et al., 2000). Thus the authors conclude that, 
"the the iohexol test is a superior activity marker compared to the lactulose-mannitol ratio" 
(Halme et al., 2000). 
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2. Experimental Study 
 2.1 Study aims 
 
The goal of the study was to measure running-induced changes in intestinal permeability and 
permeability marker LPS and investigate their association with gastrointestinal symptoms. A 
secondary aim was to inspect possible correlations between intake of certain nutrients and 
experiencing gastrointestinal symptoms. 
2.2 Materials and methods 
2.2.1 Selection of study participants  
 
Study participants were recruited by a recruitment notice (Suppl 1) posted in online running 
groups. Voluntary participants received an informational letter about the study (Suppl 2), a 
consent form (Suppl 3), and a symptom history questionnaire (Suppl 4) used to determine the 
participant’s suitability for the study. Consenting volunteers suitable to the study were selected 
as participants. Persons with a diagnosed gastrointestinal illness or asthma, heart, or 
cardiovascular diseases were excluded from participation. Pregnant or breastfeeding women 
were also excluded as well as persons with iodine allergy because of the iohexol used in 
determining permeability.  
The participants were 24- to 44-year-old active male and female runners. The average age of the 
participants was 33 years. A total of 24 participants were recruited based on the sample size of 
20 used by Nieuwenhoven et al. (2003) to detect a significant difference in intestinal 
permeability between symptomatic and asymptomatic athletes. The final sample size of our 
study was 17 participants after 7 participants dropped out due to injury or illness. Of the 17 
participants completing the study, 9 were male and 8 were female.  
The study was conducted in adherence to the ethical regulations outlined in the Declaration of 
Helsinki. Ethical approval was obtained from the HUS Coordinating ethical committee.  
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2.2.2 Study design  
 
The study protocol is outlined in Table 1 (p.35). Study participants were allocated into two 
groups, symptomatic (gastrointestinal symptoms >50% of runs, n=8) and asymptomatic 
(gastrointestinal symptoms <10% of runs, n=9), based on their completion of a symptom history 
questionnaire. The symptom history questionnaire probed the severity of the symptoms as well 
as possible gastrointestinal symptom associations with certain food items. Baseline samples at 
rest were taken from participants approximately three weeks before the running test. At this visit, 
a blood sample was taken and intestinal permeability measurement (Measurement of intestinal 
permeability, pp. 37) was started. The subjects returned the urine sample as well as a fecal 
sample the next day. Subjects were also instructed to keep a food diary for three days before the 
baseline measurements. The food diary was repeated for three days before the running test day. 
During the test day, intestinal permeability measurement was started before the running test 
where subjects ran for 90 minutes at 80% of their best 10 km race speed. After the run, a blood 
sample was taken. The subjects also received a symptom questionnaire (Suppl 5) where they 
were asked to score on a visual analog scale (VAS) how much stomach pain they experienced 
during the run. Gastrointestinal symptom occurrence during the run was also reported as well as 
gastrointestinal symptoms experienced later that day. The next day, participants returned the 
urine sample, fecal sample and completed symptom questionnaire. The study duration for 
subjects was approximately a month with four test-site visits.  
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Table 1. Timeline and study protocol 
DAY Procedure, collected samples 
-23 Food diary 1:day 1  
-22 Food diary 1:day 2 
-21 1. Meeting 
Food diary 1:day 3  
Intestinal permeability measurement ( iohexol, 24h urine collection)  
Blood sample  
-20 2. Meeting  
24h urine sample collection 
Fecal sample collection 
-2 Food diary 2 :day 1  
-1 Food diary 2 :day 2 
Test day 3. Meeting  
Food diary 2 :day 3  
90 min run at approximately 80% of 10k PR speed  
Intestinal permeability measurement ( iohexol, 24h urine collection)  
Blood sample  
1 4. Meeting  
24h urine sample collection 
Fecal sample collection 
Symptom questionnaire collection  
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2.2.3 Serum sample 
 
A blood sample was taken from the subjects approximately three weeks before the running test 
day at rest and then immediately after the running test. The blood sample volume was at most 5 
ml. The blood samples were collected in serum separation tubes (VenoSafe Clot Act. (Z), 
Terumo Europe, Leuven, Belgium) by a licensed physician. Serum was separated by 
centrifugation (1500 g, 10 min), collected and stored in -80C for later analysis. 
2.2.4 Fecal sample  
 
The study subjects were asked to provide a fecal sample at rest approximately three weeks before 
the running test and then after the running test. The subjects were given written instructions and 
they collected the first fecal sample after iohexol ingestion independently at home in a provided 
specimen container. The samples were returned the next day and stored in -20C for later 
analysis. Fecal samples were collected for Calprotectin measurement but were not analyzed in 
this thesis.  
2.2.5 Food diary 
 
The subjects were asked to keep a food diary for three days before the baseline measurements 
and for three days before the running tests. All food and drink was recorded in the food diary. 
The participants were provided with detailed instructions for completion of the food diary which 
was returned by the participants either electronically or in person during sample collection. Food 
diaries were analyzed using Fineli Ruokakori (Foodbasket) database 
(http://www.fineli.fi/foodbasket.php) for average intake of macronutrients and selected 
micronutrients over each three-day food diary period. Daily intake of nutrients and group 
averages were calculated in Excel from the obtained data.  
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2.2.6 Running test day 
 
During the running test day, the subjects ran for 90 minutes at a challenging pace which was 
suggested as approximately 80% of the speed of their best 10 km race time. The effort should 
have been challenging, but able to be maintained for the full 90 minutes. The running pace was 
determined individually by the athlete according to their perceived exertion. After the running 
test, subjects received a symptom questionnaire to fill out possible gastrointestinal symptoms. 
The rest of the form concerning the appearance of gastrointestinal symptoms later during the day 
was completed at home and returned the next day.     
2.2.7 Measurement of intestinal permeability 
 
The intestinal permeability was determined through oral administration of a contrast agent, 
iohexol (Omnipaque 350, 755 mg iohexol/ml, GE Healthcare, Oslo, Norway). Subjects drank a 
glass of water to which 50 ml iohexol had been added. Urine was collected for 24 hours after 
administration of the iohexol drink. The collection was performed at the baseline measurement 
and during the running test day. To improve the reliability of the measurement, subjects were 
instructed not to eat two hours before and three hours after the testing. Drinking of liquids was 
not restricted. The subjects were given instructions and a collection container for the urine 
collection which was then returned the next day. The amount of urine was recorded, the urine 
was stirred and two 5 ml samples were collected. These samples were stored in -20C for later 
analysis. Because non-steroidal anti-inflammatory medications and alcohol are known to affect 
intestinal permeability, subjects were asked to abstain from use the day before and during the 
measurements. Iohexol was administered in the presence of a doctor because it contains iodine, 
which can in some instances trigger an allergic reaction. The test location was also equipped for 
first-aid administration. Possible contrast medium-induced gastrointestinal symptoms were 
viewed as a minor disadvantage as the use of iohexol in permeability studies is widely accepted 
and used in literature.   
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2.2.8 Measurement of iohexol from urine 
 
The iohexol concentrations in the urine were measured using the Iohexol enzyme-linked 
immunosorbent assay (ELISA) kit (BioPAL, Worcester, MA, USA) according to the kit 
instructions. First, the urine samples were prepared by diluting them 1:1000 in dilution buffer 
(0.1% bovine serum albumin in PBS) so that they fell within the active region of the standard 
curve. Then 50μl iohexol standards and diluted urine samples were pipetted on to the 96-well 
plate. This was followed by pipetting of 50μl rabbit anti-iohexol into all wells except blanks and 
incubating on an orbital shaker for 1 hour. After completion of the 1-hour incubation period, the 
solutions were aspirated from all wells and the plate was washed with 350 μl Wash Buffer 
(0.05% Tween 20 in PBS) per well for a total of three times. After washing, 100μl Goat anti-
rabbit IgG-HRP was pipetted into all wells except blanks and the plate was incubated on an 
orbital shaker for 30 minutes. Again, the solutions were aspirated from all wells and the plate 
was washed with 350 μl Wash Buffer per well for a total of three times. Then 100μl HRP 
Substrate Reagent was pipetted into all wells including blanks and the plate was tapped gently to 
mix contents of each well. The substrate was incubated once more for 30 minutes at room 
temperature with no shaking. After incubation, 100μl of HRP Stop Reagent was pipetted into all 
wells including blanks. The plate was read at 450nm (Wallac Victor
2 
1420 Pertin Elmer 
Multilabel counter, Waltham MA, USA) and the concentration of iohexol in the samples was 
determined from the standard curve. Intestinal permeability to iohexol was then assessed by 
calculating the percentage of excreted iohexol using the following equation: 
Iohexol (%) = amount of excreted iohexol in urine after 24h (mg) / amount of administered 
iohexol (mg) * 100 
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2.2.9 Measurement of zonulin from serum 
 
Zonulin was measured using the Zonulin ELISA test kit (Immundiagnostik, Bensheim, 
Germany) according to the kit instructions. Serum samples were prepared by adding 475 μl 
dilution buffer to 25 μl sample. Then 150 μl of the sample solution was added to 150 μl tracer 
before vortexing. Controls and standards were prepared similarly by adding 150 μl of either 
standard or control to 150 μl of the tracer and mixing well. To begin the ELISA procedure, 100 
μl of the prepared standards, controls or samples were pipetted into each well. Then the strips 
were covered and the plate was incubated for 1 hour while shaking on a horizontal shaker at 550 
rpm at room temperature. After incubation, the microtiter plate was washed five times with 250 
μl wash buffer. Then 100 μl conjugate was added into each well. Again, the plate was incubated 
for 1 hour while shaking on a horizontal shaker at 550 rpm at room temperature and washed five 
times with 250 μl wash buffer after the incubation. Then 100 μl of substrate solution was added 
into each well. The plate was incubated once more for 15 minutes at room temperature. After 
incubation 100 μl of stop solution was added into each well. The color changed from blue to 
yellow with the intensity of the yellow color being inversely proportional to zonulin 
concentration in the sample. The absorption was determined promptly with a photometer at 450 
nm (Wallac Victor2 1420 Pertin Elmer Multilabel counter, Waltham MA, USA) and the 
concentration of zonulin was determined from the standard curve.  
2.2.10 Inflammatory markers: LPS 
 
LPS was analyzed using a LAL (Limulus amebocyte lysate) Chromogenic Endpoint Assay 
(Hycult biotech, Uden, Netherlands) according to the kit instructions. Analysis was performed at 
the University of Helsinki Institute of Dentistry. To start the ELISA protocol, 50 μl in duplicate 
from both the diluted sample (1:5) and controls were transferred to the assigned wells. Then 50 
μl reconstituted LAL reagent was added to each well except for sample controls which received 
50 μl endotoxin free water instead of LAL reagent. The plate was then covered and incubated for 
30 minutes at room temperature. Then the samples were measured at 405 nm and endotoxin 
concentrations were determined from the standard curve.         
40 
 
2.2.11 Data Analysis 
 
Differences between symptomatic and asymptomatic groups were analyzed using independent 
samples t-test. Differences within groups from baseline to running test measurements were 
analyzed using paired samples t-test. Statistical significance (p < 0.05) for collected data was 
determined using PASW Statistics software version 18.0.2. (IBM, Armonk, NY, USA).         
 
3. Results 
3.1 Symptom questionnaires 
3.1.1 Background questionnaire 
 
Symptom frequency was rated on a scale of one to five ranging from never experiencing 
symptoms to always experiencing symptoms. The average symptom frequency for the 
asymptomatic participants was 1.9. The average symptom frequency for symptomatic 
participants was 3.9 (Table 2). The reported frequency of gas and diarrhea was also significantly 
higher in the symptomatic than the asymptomatic group (Table 3 and Table 4). Likewise, the 
frequency of symptoms from fruit, vegetables, bread, and spicy foods was significantly higher in 
the symptomatic group (Table 6). Stool consistency was reported as loose in eight of the 
seventeen runners in the background questionnaire. Two reports were from the asymptomatic 
group and six from the symptomatic group. The remaining seven runners in the asymptomatic 
group all reported normal stool consistency.  
3.1.2 After run questionnaire 
 
After the run, the symptomatic group reported significantly more (2.00 cm) stomach pain than 
the asymptomatic group (0.30 cm) as measured by a visual analogue scale (p < 0.05). Stool 
consistency after the run was loose in ten of the seventeen runners, with five reports from each 
group (Table 5). The asymptomatic group also reported three counts of normal stool and one 
count of hardened stool. The symptomatic group reported two counts of hardened stools and one 
count of diarrhea.  
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Average running paces during the running test were comparable in both groups. The average 
pace for the control group was 5min 12sec per kilometer. The average pace for the symptomatic 
group was 5min 02sec per kilometer.  
Table 2. Gastrointestinal symptom frequency in 
control (asymptomatic) vs. symptomatic runners 
rated on a scale from 1 (never) to 5 (always).  
 
 
Table 3. Running-induced diarrhea 
frequency in control (asymptomatic) vs. 
symptomatic runners rated on a scale from 
1 (never) to 5 (always). 
       
   
Rating  
Control  
(n=9) 
Symptom  
(n=8) 
 
Rating  
Control
(n=9) 
Symptom 
(n=8) 
1 1 0 
 
1 4 0 
2 8 0 
 
2 5 1 
3 0 2 
 
3 0 1 
4 0 5 
 
4 0 5 
5 0 1 
 
5 0 1 
  
 
 
 
 
    Table 4. Gas frequency in control (asymptomatic) 
vs. symptomatic runners rated on a scale from 1 
(never) to 5 (always). 
 
Table 5. Stool consistency in control 
(asymptomatic) and symptomatic runners 
after running 
       
   
Rating  
Control 
 (n=9) 
Symptom  
(n=8) 
 
Rating    
Control 
(n=9) 
Symptom 
(n=8) 
1 2 1 
 
loose 5 5 
2 5 0 
 
diarrhea 0 1 
3 1 1 
 
hard 1 2 
4 1 6 
 
normal/firm 3 0 
5 0 0 
 
normal but 
urgent 0 0 
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Table 6. Gastrointestinal symptoms from food questionnaire. Gastrointestinal symptoms 
occurring during running following ingestion of various foods rated on a scale from 1 (never) to 
5 (always). 
Gastrointestinal symptoms from food questionnaire 
 Fruit Vegetable Bread Spicy food 
Rating Control Symptom Control Symptom Control Symptom Control Symptom 
1 5 0 5 0 4 0 3 0 
2 3 3 4 2 4 1 2 0 
3 1 2 0 3 1 3 2 0 
4 0 3 0 3 0 3 0 5 
5 0 0 0 0 0 0 1 2 
 
 
3.2 Intestinal permeability  
 
Intestinal permeability increased significantly in all runners from baseline to after run 
measurement (p<0.001) as seen in Figure 6 (p.43). Average asymptomatic group baseline 
iohexol concentration was 0.21% (SD=0.17%) vs. 0.38% (SD=0.23%) after running. Average 
symptom group baseline iohexol concentration was 0.20% (SD=0.07%) vs. 0.36% (SD=0.12%) 
after running. There was no significant difference in the increase in permeability between the 
symptomatic and asymptomatic group.  
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Figure 6. A. Iohexol permeability in all subjects at baseline vs. after running test with average 
and standard deviation (***p < 0.001). B. Iohexol permeability in control (asymptomatic) and 
symptomatic groups separately at baseline (red color) and after running (green color) with 
average and standard deviation (*p < 0.05). 
 
3.3 Zonulin 
 
Serum zonulin concentrations were significantly higher in the asymptomatic group (67.5 ng/ml, 
SD=18.2) than in the symptomatic group (51.3 ng/ml, SD=14.6) following the run (p < 0.05). 
Serum zonulin concentration in the asymptomatic group was also significantly higher after the 
run (67.5 ng/ml, SD=18.2) compared to baseline (53.6 ng/ml, SD=24.9) ( (p < 0.05) as seen in 
Figure 7 (p.44). No significant differences were found between the groups at baseline or in the 
total zonulin concentration change from baseline to after the run in combined groups.  
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Figure 7. A. Serum zonulin concentrations in all subjects at baseline and after running with 
average and standard deviation. B. Serum zonulin concentrations in control (asymptomatic) and 
symptomatic groups separately at baseline (red color) and after running (green color) with 
average and standard deviation (*p <  0.05). 
 
3.4 LPS  
 
Serum LPS concentrations were significantly higher at baseline in the symptomatic group (0.767 
EU/ml, SD=0.119) than in the asymptomatic group (0.567 EU/ml, SD=0.124) (p < 0.005) as 
seen in Figure 8 (p. 45). There was no significant difference in serum LPS concentrations 
between the groups after the run. 
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Figure 8. A. Serum LPS concentrations in all subjects at baseline and after running  with average 
and standard deviation. B. Serum LPS concentrations in control (asymptomatic) and 
symptomatic groups separately at baseline (red color) and after running (green color) with 
average and standard deviation (**p < 0.01). 
 
3.5 Food diaries 
 
There were no statistically significant differences between asymptomatic and symptomatic 
groups in the average intake of various nutrients at baseline or at the running test (Table 7). 
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Table 7. Average nutrient intake and standard deviation in control and symptomatic groups at 
baseline and running test measurements (Mean ± SD). 
Nutrient Measurement 
Control 
baseline 
Symptom 
baseline Control run Symptom run 
energy kcal 2787 ± 542 2580  ± 871 2918  ± 972 2581  ± 1106 
carbohydrate 
(absorbable) 
g 
304 ± 122 293  ± 102 342  ± 184 259  ± 112 
fat g 100 ± 37 92  ± 53 100  ± 35 112  ± 71 
protein g 129  ± 33 119  ± 41 123  ± 36 113  ± 36 
alcohol g 4  ± 5 0  ± 0 2  ± 2 1  ± 2 
fiber g 51  ± 44 40  ± 25 57  ± 53 30  ± 13 
fiber, insoluble g 30  ± 26 24  ± 14 34  ± 30 19  ± 9 
calcium mg 1328  ± 612 1282  ± 366 1398  ± 555 1225  ± 498 
iron mg 24  ± 26 20  ± 10 26  ± 14 18  ± 8 
iodine µg 218  ± 83 193  ± 79 209  ± 85 218  ± 89 
potassium mg 6830  ± 4434 5432  ± 1897 7041  ± 5499 4536  ± 1472 
magnesium mg 709  ± 431 595  ± 265 767  ± 516 502  ± 161 
sodium mg 3138  ± 1003 2318  ± 1140 2993  ± 1029 2817  ± 1061 
salt mg 7908  ± 2554 5895  ± 2906 7458  ± 2405 7165  ± 2688 
phosphorus mg 2275  ± 768 2143  ± 558 2328  ± 852 1986  ± 636 
selenium µg 117  ± 70 180  ± 266 110  ± 28 89  ± 39 
zinc mg 15  ± 4 14  ± 4 16  ± 4 14  ± 4 
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4. Discussion and future prospects 
 
The aim of our study was to measure running-induced changes in intestinal permeability and 
permeability marker LPS and investigate their association with gastrointestinal symptoms. A 
secondary objective was to inspect possible correlations between gastrointestinal symptom 
occurrence and intake of certain nutrients. Participant allocation to the symptomatic and 
asymptomatic groups was based on the differences in reported symptom frequency and provided 
a good starting point for the detection of differences among the two groups. Both groups 
experienced a significant increase in intestinal permeability from baseline to after run 
measurement. However, there was no significant difference between the intestinal permeability 
in the two groups after the run. This result was in contrast to the findings of Nieuwenhoven et. al 
(2003) who reported higher intestinal permeability in symptomatic than asymptomatic athletes. 
To our best knowledge, this is the only other study comparing intestinal permeability in 
symptomatic and asymptomatic athletes. The study by Nieuwenhoven et al (2003) measured 
intestinal permeability via the use of sugar probes whereas our study measured intestinal 
permeability using iohexol, which was deemed a more reliable measure of intestinal permeability 
by Halme et al. (2000). The discrepancy in results indicates that more studies are needed to 
understand the relationship between gastrointestinal symptoms and intestinal permeability. The 
sample size in our study was relatively small, but comparable to other permeability studies. The 
significant increase in intestinal permeability in the symptomatic and asymptomatic groups in 
our study may explain the high incidence of stool consistency changes that were observed in 
both groups. The increase in intestinal permeability in both the symptomatic and asymptomatic 
groups suggests that the damage to the epithelia and subsequent increase in permeability is a 
normal response to running. However, perhaps the differences in symptom occurrence are a 
result of individual differences in ability to repair that damage after exercise. Research into 
intestinal epithelium recovery rate after exercise could help determine the variability in 
individual repair ability and whether this repair ability is tied to the development of 
gastrointestinal symptoms. Whether the difference in intestinal recovery is caused by genetic 
factors or by some unrelated pathology is also unclear and a source of further study.  
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In the symptom history questionnaires, most symptomatic athletes reported experiencing loose 
stools after running while only two asymptomatic runners reported loose stools. However, after 
the running test loose stools were reported equally by both groups with over half of runners 
reporting the symptom. Despite both groups experiencing changes in stool consistency, the 
change was accompanied by significantly more stomach pain in the symptomatic group which 
may indicate that the severity of the symptoms was not as high in the asymptomatic group. The 
asymptomatic group also included four runners with no stool changes at all while all runners in 
the symptomatic group reported stool changes. Clearly, the symptomatic group experienced 
more pain and changes in stool consistency but the cause is still unknown due to the lack of 
difference in intestinal permeability change between the two groups. Serum zonulin 
concentration increased significantly in the asymptomatic group after running compared to both 
the baseline measurements within the group as well as the measurements after running in the 
symptomatic group. Further studies are warranted to confirm and interpret the cause of the 
observed zonulin increase as zonulin has been previously shown to contribute to the regulation of 
intestinal barrier function and is up-regulated in various autoimmune conditions such as Crohn's 
Disease and Type I Diabetes  (Fasano, 2011; Sapone et al., 2006). Additionally, exposure to 
bacteria in the intestine is a powerful trigger for zonulin release (Fasano, 2011).  
The largest difference in reported symptom frequency between the groups occurred with gas and 
diarrhea. Most symptoms were reported from fruit, vegetables, bread, and spicy foods which 
indicates that symptomatic runners may benefit from avoidance of these foods before running to 
decrease symptom occurrence. However, as response to various foods varies greatly between 
people, no universal recommendation can be made and athletes should instead be encouraged to 
experiment on their own body's reaction to these foods. Complete avoidance of these foods 
would be unadvised as many of them exert positive effects on health and should be included in 
the diet regularly. Therefore it is important to focus on avoiding these food types only before 
runs and eating them at other times throughout the day. While research is still in its infancy, it 
has been suggested that nitric oxide, which improves intestinal perfusion, could be used to 
reduce gastrointestinal symptoms in athletes (Oliveira et al., 2014). However, a problem with 
this strategy is that current vegetable sources of dietary nitrate are sometimes associated with 
gastrointestinal symptoms (Oliveira et al., 2014). There is also indication that ingesting multiple 
carbohydrates reduces gastrointestinal symptoms compared to a single carbohydrate source 
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(Oliveira et al., 2014). Analysis of the food diaries indicated that there were no significant 
differences in intake of various nutrients between symptomatic and asymptomatic runners. Some 
of the factors examined included macronutrients, dietary fiber, and minerals. The similarity in 
the two groups' nutrient intake indicates that there is some sort of individual predisposition to 
develop symptoms and that symptoms are not caused by diet alone. Rather, it seems that certain 
foods aggravate symptoms and are poorly tolerated in those individuals with a predisposition for 
gastrointestinal problems.  
Another factor besides individual predisposition that may contribute to the increased rate of 
symptoms in the symptomatic group is the elevation of serum LPS concentrations at rest. While 
there was no difference in LPS concentrations between the groups after running, the plasma LPS 
concentrations at rest were significantly higher in the symptomatic group. The observed increase 
in serum LPS concentrations following strenuous exercise is consistent with previous studies 
(Bosenberg et al., 1988; Brock-Utne, 1988; Jeukendrup et al., 2000). Serum LPS concentrations 
rise as exercise-induced damage to the intestinal epithelia prevents leakage of LPS into the blood 
stream.  The bacterial LPS toxins then trigger a host inflammatory response and have been 
hypothesized to cause many of the symptoms experienced by endurance athletes such as 
dizziness, nausea, stomach ache, intestinal cramps and diarrhea (Jeukendrup et al., 2000). Thus, 
it is plausible that the increase in symptoms reported by the symptomatic group was at least 
partially caused by chronically higher concentrations of serum LPS and subsequent 
inflammation. This hypothesis is supported by Brock-Utne's (1988) work, where 80.6% of 
runners with high LPS levels (0,329 ± 0,026 ng/ml) experienced gastrointestinal symptoms while 
only 17.7% of those with low LPS levels (0,075 ± 0,005 ng/ml) experienced symptoms. The lack 
of difference between the LPS concentrations in the two groups after the run may be explained 
by the fact that the symptomatic group’s LPS concentrations were already high at rest. Thus, 
they did not increase further above the high baseline level whereas the low baseline LPS 
concentrations in the asymptomatic group increased to the same higher level in response to the 
trauma caused by strenuous long-duration running. It is still unclear whether the high baseline 
LPS concentrations were caused by the mechanical damage created by training and an inability 
of the intestinal mucosa to repair that damage or if those runners with elevated LPS 
concentrations have some other underlying pathology which leads to gastrointestinal problems 
during running. If some other pathology leads to gastrointestinal symptoms during running, then 
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identifying and addressing that problem may be of greatest benefit to athletes struggling with 
gastrointestinal symptoms.   
No difference was found in the average running pace between the two groups during the running 
test while both groups experienced an increase in intestinal permeability, indicating that the 
running effort was quite uniform between the groups and was not likely to influence the 
permeability results. Overall, our study suggests that running produces similar changes in the 
intestinal mucosa in all runners but that those runners experiencing symptoms have an individual 
predisposition for symptom occurrence which may be caused by impaired epithelial membrane 
recovery after exercise-induced damage or by some other underlying pathology. A genetic factor 
in gastrointestinal symptom occurrence has also been suggested previously due to a strong 
correlation of gastrointestinal complaints and gastrointestinal symptom history (Oliveira et al., 
2014). Developing strategies to minimize symptom occurrence is important due to the high 
symptom incidence among runners and the negative effects of gastrointestinal symptoms on 
sport performance (Jeukendrup et al., 2000; Stuempfle and Hoffman, 2015). Based on the 
symptom history questionnaires, it may be advisable for some runners to avoid certain foods 
which aggravate their symptoms. These foods must be identified on an individual basis but it 
appears that fruit, vegetables, bread, and spicy foods are commonly identified as a cause of 
gastrointestinal distress. At this time avoiding symptom-aggravating foods remains the most 
effective treatment for prevention of running-induced gastrointestinal distress. Adding probiotics 
to the diet may also improve symptoms by strengthening the integrity of intestinal mucosa 
(Kainulainen et al., 2015; Karczewski et al., 2010; Lamprecht et al., 2012).  
5. Conclusion 
 
No significant difference was found in intestinal permeability between symptomatic and 
asymptomatic runners either at rest or following strenuous exercise. However, both groups 
experienced a significant increase in intestinal permeability from baseline to after running. 
Higher symptom occurrence in the symptomatic group may be caused by higher resting serum 
LPS concentrations. LPS in the bloodstream triggers a host inflammatory response which has 
been proposed to lead to gastrointestinal symptom occurrence in athletes (Jeukendrup et al., 
2000). Comparison of average intake of various nutrients between the two groups showed no 
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significant differences, indicating an individual predisposition as the cause of symptoms rather 
than diet alone. The lack of difference in intestinal permeability between the groups combined 
with the difference in symptom occurrence indicates that intestinal permeability changes alone 
do not account for symptom development. A possible factor may be individual differences in 
intestinal mucosa repair ability or some underlying pathology.  
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8. Supplements 
8.1 Supplement 1 
HEI JUOKSIJA! 
 
OSALLISTU TUTKIMUKSEEN, JOSSA SELVITETÄÄN JUOKSIJOIDEN VATSAVAIVOJEN SYITÄ 
 
Haemme vapaaehtoisia juoksijoita keväällä 2015 Helsingin Yliopiston Lääketieteellisen 
tiedekunnan Medicum-yksikössä toteutettavaan tutkimukseen, jossa selvitetään juoksijoiden 
juoksun aikaisten vatsavaivojen syitä. 
Tutkimukseen haetaan sekä oireettomia juoksijoita että juoksijoita, jotka kärsivät usein 
vatsaoireista juostessaan. Vatsaoireet voivat olla esimerkiksi kipua, pahoinvointia, ripulia, 
oksentelua, hölskymistä tai muita vaivoja. Noin kuukauden kestävän tutkimuksen aikana Teille 
tulee noin 4 tutkimuskäyntiä, johon kuuluvat lähtötilannekartoitus, varsinainen testipäivä ja kotona 
itse otettavien näytteiden ja lomakkeiden palautuskerrat. Teitä pyydetään myös täyttämään 
ruokapäiväkirjaa kolmelta päivältä ennen lähtötilannekartoitusta sekä kolmelta päivältä ennen 
varsinaista testipäivää. Tutkimuksen aikana Teiltä otetaan yhteensä kaksi verinäytettä sekä Teitä 
pyydetään toimittamaan kaksi ulostenäytettä. Suolistonne seinämän läpäisevyys mitataan kahdesti 
juotavan varjoaineliuoksen avulla. Varjoaineen pitoisuus määritetään 24 h aikana kotona 
kerättävästä vuorokausivirtsasta. Tutkimuksessa käytetty varjoaine on tutkimuksissa todettu 
turvalliseksi ja luotettavaksi. Varsinaisena testipäivänä osallistutte 90 minuutin mittaiseen 
juoksumattotestiin, joka suoritetaan 80% vauhdilla arvioimastanne 10 kilometrin matkan 
ennätysvauhdistanne. 
Pyydämme Teitä osallistumaan tähän tutkimukseen, jos olette iältänne 18-45 -vuotias terve 
aktiivijuoksija. Sovellutte tutkimukseen, jos kärsitte juoksusuorituksen aikana usein vatsaoireista 
tai, jos koette vatsaoireita juoksun aikana vain harvoin tai ette ollenkaan. Tutkimukseen 
osallistuminen edellyttää, että Teillä ei ole diagnosoitua suolistosairautta, astmaa ja/tai sydän- ja 
verisuonisairauksia. Tutkimus ei sovellu raskaana oleville tai imettäville. Tutkimuksessa 
käytettävän varjoaineen takia Teillä ei myöskään saa olla yliherkkyyttä jodille tai jodiallergiaa. 
Tutkimuksesta vastaa tutkimusjohtaja, professori Riitta Korpela. Tutkimuksen aikana Teille 
mahdollisesti aiheutuneet matkakulut kotoa tutkimuspaikalle korvataan. Varsinaiset 
tutkimuskäynnit ovat maksuttomia. Tutkimus suoritetaan Helsingissä. 
Mikäli olette kiinnostunut osallistumaan tutkimukseen, ota yhteyttä: 
Projektitutkija Elisa Karhu 
050-3180279 
elisa.karhu@helsinki.fi 
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8.2 Supplement 2 
TIEDOTE TUTKITTAVILLE 
 
“Liikuntasuorituksen aiheuttamat muutokset suoliston läpäisevyydessä vatsaoireilevilla ja 
ei-oireilevilla juoksijoilla” 
 
TUTKIMUKSEN KUVAUS 
 
Tutkimuksen tarkoituksena on selvittää juoksijoiden yleisesti kokemien vatsavaivojen syitä. 
Tutkimuksen päätavoitteena on mitata juoksusuorituksen aiheuttamia muutoksia suoliston 
seinämän läpäisevyydessä ja määrittää niiden mahdollinen vaikutus vatsaoireiden ilmaantumiseen 
juoksusuorituksen aikana. Läpäisevyyttä mitataan juotavan varjoaineen avulla, joka imeytyy 
suolistosta verenkiertoon ja poistuu elimistöstä virtsan mukana. Lisääntynyt varjoaineen pitoisuus 
virtsassa merkitsee suoliston läpäisevyyden lisääntymistä. Tutkimuksessa käytettävä varjoaine on 
yleisesti käytössä sairaaloissa kuvantamisessa ja sen todettu olevan turvallinen ja luotettava 
suoliston läpäisevyyden mittaamiseen. 
 
Tutkimuksessa on tarkoitus verrata läpäisevyyden muutoksia juoksusuorituksen aikana yleensä 
vatsaoireita kokevien juoksijoiden ja oireettomien juoksijoiden välillä. Tämän hetkisen tiedon 
mukaan korkealla intensiteetillä suoritettava liikunta lisää suoliston seinämän läpäisevyyttä, mutta 
sen yhteys vatsaoireiden ilmaantumiseen on vielä epäselvä. Tutkimuksen toisena tavoitteena on 
selvittää mahdollisia ruoka-aineita, jotka voisivat olla yhteydessä vatsaoireiden kokemiseen 
juoksusuorituksen aikana. Tutkimuksessa määritetään myös verestä mitattavien tulehdusta 
kuvaavien aineiden pitoisuuden lisääntyminen juoksusuorituksen aikana. Tiettyjen tulehdusta 
kuvaavien aiheiden tiedetään korreloivan suoliston läpäisevyyden lisääntymisen sekä 
vatsaoireiden ilmaantumisen kanssa. Yhdessä näiden muutosten tutkiminen oireilevien ja ei-
oireilevien juoksijoiden välillä edesauttaa terapeuttisten ja ennaltaehkäisevien hoitojen kehitystä 
liikunnasta aiheutuviin vatsaoireisiin. 
 
TUTKIMUKSEEN OSALLISTUMINEN 
 
Pyydämme Teitä osallistumaan tähän tutkimukseen, jos olette iältänne 18-45 -vuotias terve 
aktiivijuoksija. Sovellutte tutkimukseen, jos kärsitte juoksusuorituksen aikana usein vatsaoireista 
(kipu, ripuli, oksentelu) tai jos koette vatsaoireita juoksun aikana vain harvoin tai ette ollenkaan. 
Tutkimukseen osallistuminen edellyttää, että Teillä ei ole diagnosoitua suolistosairautta, astmaa 
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ja/tai sydän- ja verisuonisairauksia. Tutkimus ei sovellu raskaana oleville tai imettäville. 
Tutkimuksessa käytettävän varjoaineen takia Teillä ei myöskään saa olla yliherkkyyttä jodille tai 
jodiallergiaa. 
 
TUTKIMUKSEN KULKU 
 
Teidät jaetaan tutkimuksen alussa täytettävän taustakyselyn perusteella joko yleensä 
juoksusuorituksen aikana vatsaoireileviin tai ei-oireileviin. Tutkimukseen kuuluu 
lähtötilannemittaus sekä varsinainen testauspäivä. Tutkimuksen aikana pidätte myös 
ruokapäiväkirjaa 3 päivää ennen lähtötilannemittausta sekä 3 päivää ennen varsinaista testipäivää. 
Lähtötilannemittauksessa Teiltä otetaan verinäyte sekä Teidän suolistonne seinämän 
läpäisevyyden määritys aloitetaan juomalla  lasi vettä, johon on sekoitettu 50 ml ioheksoliliuosta. 
Juomisen jälkeen aloitetaan 24 h virtsankeruu, joka tehdään kotona. Lähtötilannemittausta 
seuraavana päivänä toimitatte 24 h aikana keräämänne virtsan sekä päivän ensimmäisen 
ulostenäytteen tutkimuspaikalle. Näitä varten saatte ensimmäisellä kerralla mukaanne 
keräysastiat. Varsinaisena testipäivänä juotte jälleen 50 ml ioheksoliliuosta, jonka jälkeen juoksette 
90 minuuttia juoksumatolla 80% vauhdilla arvioimastanne 10 kilometrin matkan 
ennätysvauhdistanne. Juoksusuorituksen jälkeen Teiltä otetaan verinäyte. Saatte myös 
vatsaoirekyselyn kotiin täytettäväksi. Testipäivän seuraavana päivänä toimitatte 24 h keräämänne 
virtsan, täytetyn vatsaoirekyselylomakkeen sekä päivän ensimmäisen ulostenäytteen.  
 
Toivomme, että ette muuta tutkimuksen aikana tavanomaista ruokavaliotanne, vaan syötte niin 
kuin tavallisestikin söisitte. Pyydämme Teitä välttämään tulehduskipulääkkeiden, kuten Burana ja 
Ibusal, ja alkoholin käyttöä suoliston seinämän läpäisevyyden mittausta edeltävänä päivänä ja 
mittauksen aikana. Mittauspäivinä tulisi myös välttää raskasta fyysistä rasitusta. 
Kokonaisuudessaan Teille tulee tutkimuksen aikana noin 4 käyntiä tutkimuspaikalla ja Teille 
mahdollisesti aiheutuneet matkakulut kotoa tutkimuspaikalle korvataan. Tutkimus suoritetaan 
Helsingissä. 
 
OSALLISTUMISEN VAPAAEHTOISUUS JA OSALLISTUMISEN KESKEYTTÄMINEN 
 
Tutkimukseen osallistuminen on täysin vapaaehtoista. Voitte myös keskeyttää osallistumisenne 
milloin tahansa tutkimuksen aikana syytä ilmoittamatta. Jos päätätte keskeyttää tutkimukseen 
osallistumisenne, Teistä siihen mennessä kerättyä tietoja voidaan silti käyttää. 
 
65 
 
TIETOJEN LUOTTAMUKSELLISUUS 
 
Kaikki tutkimuksessa kerätty tieto on luottamuksellista eikä tutkimustuloksista voi tunnistaa 
yksittäistä henkilöä. Ainoa tutkimusrekisteriin jäävä tieto on tässä tutkimuksessa syntyvää, 
taustatietoja ei kerätä sairaalan tai terveyskeskuksen potilasrekisteristä eikä mistään muustakaan 
tiedostosta. Tutkimuksessa kerättäviä tietoja voidaan käsitellä myös muualla kuin tiedot keränneen 
tutkijan, Helsingin Yliopiston Lääketieteellisen tiedekunnan Medicum-yksikössä. Tällöin tiedot ovat 
koodatussa muodossa eikä yksittäisen henkilön tunnistaminen ole mahdollista. Tutkimuksen 
tuloksia käytetään tieteelliseen raportointiin (esim. tiedejulkaisut) vain sellaisessa muodossa, jossa 
yksittäistä tutkittavaa ei voi tunnistaa. 
 
MAHDOLLINEN HYÖTY JA RISKIT 
 
Tämän tutkimuksen tarkoituksena on saada tietoa liikunnan aikaisten vatsaoireiden 
ilmaantumisesta ja siten edesauttaa ennaltaehkäisevien hoitojen kehitystä näihin vaivoihin. 
Tutkimuksen aikana otetut verikokeet saattavat aiheuttaa epämukavuutta, mutta ne eivät vaikuta 
terveydentilaanne. Suoliston läpäisevyyden mittaamisen yhteydessä joudutte olemaan noin 5 h 
syömättä, mutta mittaus pyritään suorittamaan siten, että tämä lyhyt paasto ajoittuu luonnollisesti 
aterioiden väliin. 
 
TUTKIMUKSEN EETTISYYS 
Eettinen toimikunta on antanut tutkimuksesta puoltavan lausunnon.  
LISÄTIETOJA 
 
Mahdollisiin kysymyksiin tutkimuksesta vastaa 
 
Projektitutkija: Elisa Karhu 
Puhelinnumero: 050-3180279 
 
Tutkimuksesta vastaava henkilö: Professori Riitta Korpela 
Puhelinnumero: 029 4125354 
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8.3 Supplement 3 
 
SUOSTUMUS TUTKIMUKSEEN OSALLISTUMISESTA 
 
Olen osallistumassa tutkimukseen “Liikuntasuorituksen aiheuttamat muutokset suoliston 
läpäisevyydessä vatsaoireilevilla ja ei-oireilevilla juoksijoilla”, jossa tutkitaan muutoksia 
vatsaoireilevien ja ei-oireilevien juoksijoiden suoliston seinämän läpäisevyydessä ja tulehdusta 
kuvaavien aineiden pitoisuuksissa juoksusuorituksen aikana. Tutkimuksessa selvitetään myös 
mahdollisia vatsaoireisiin johtavia ruoka-aineita ruokapäiväkirjan avulla.  
 
Olen saanut, perehtynyt ja ymmärtänyt tutkimuksen kirjallisen tiedotteen (versio 07012015). 
Tiedotteesta minulle on selvinnyt tutkimuksen tarkoitus ja sen aikana suoritettavat toimenpiteet. 
Olen saanut myös riittävästi suullista informaatiota ja minulla on ollut mahdollisuus esittää 
kysymyksiä tutkimuksesta.  
 
Osallistun tutkimukseen vapaaehtoisesti. Olen tietoinen siitä, että voin keskeyttää tutkimukseen 
osallistumisen missä tahansa tutkimuksen vaiheessa ennen sen päättymistä ilman, että siitä koituu 
minulle mitään haittaa. Voin myös peruttaa tämän suostumukseni, jolloin minusta kerättyjä tietoja 
ja näytteitä ei käytetä enää tutkimustarkoituksessa. Olen tietoinen, että mahdolliseen 
keskeyttämiseeni mennessä minusta kerättyjä tietoja saa käyttää osana tutkimusaineistoa. 
 
Kaikki tutkimuksessa kerätty tieto on luottamuksellista eikä tutkimustuloksista voi tunnistaa 
yksittäistä henkilöä. Ainoa tutkimusrekisteriin jäävä tieto on tässä tutkimuksessa syntyvää, 
taustatietoja ei kerätä sairaalan tai terveyskeskuksen potilasrekisteristä eikä mistään muustakaan 
tiedostosta. Tutkimuksessa kerättäviä tietoja voidaan käsitellä myös muualla kuin Helsingin 
Yliopiston Lääketieteellisen tiedekunnan Medicum-yksikössä. Tällöin tiedot ovat koodatussa 
muodossa eikä yksittäisen henkilön tunnistaminen ole mahdollista.  Ymmärrän, että 
tutkimustuloksiani saa käyttää tieteelliseen raportointiin vain sellaisessa muodossa, jossa 
yksittäistä tutkittavaa ei voi tunnistaa.  
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Allekirjoituksellani vahvistan osallistumiseni tähän tutkimukseen ja suostun 
vapaaehtoisesti tutkimushenkilöksi. 
 
Tutkimushenkilön nimi:_____________________________               Syntymäaika:______________ 
 
Kotiosoite:_______________________________________________________________________ 
 
_____________________________________                     ______________________ 
Tutkimushenkilön allekirjoitus                                                 Päiväys 
 
Suostumus vastaanotettu. 
 
_____________________________________                     ______________________ 
Suostumuksen vastaanottajan allekirjoitus                           Päiväys 
 
_____________________________________ 
Nimenselvennys 
Tästä suostumuslomakkeesta täytetään kaksi samansisältöistä kappaletta, joista toinen jää 
tutkimushenkilölle ja toinen tutkimusryhmälle. 
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8.4 Supplement 4 
TAUSTAKYSELY GUTRUN-TUTKIMUKSEEN 
 
”Liikuntasuorituksen aiheuttamat muutokset suoliston läpäisevyydessä vatsaoireilevilla ja ei-
oireilevilla juoksijoilla” 
 
HENKILÖTIEDOT 
 
 
Nimi:_____________________________________________           
Syntymäaika:_______________ 
 
Katuosoite:_____________________________________________________________________
__ 
 
Postinumero:___________________            
Postitoimipaikka:_______________________________ 
 
Sähköpostiosoite:_______________________________________________________________
___ 
 
Puhelinnumero(t):___________________________________ 
 
 
 
 
 
TUTKIMUSNUMERO:_________________________________    (Projektitutkija täyttää) 
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TUTKIMUKSEEN OSALLISTUMINEN 
 
 
Onko Teillä diagnosoitu suolistosairaus?    Kyllä Ei 
 
Jos vastasit edelliseen Kyllä, niin mikä:_______________________________________________ 
 
Onko Teillä diagnosoitu astma?    Kyllä Ei 
 
Onko Teillä diagnosoitu sydän- tai verisuonisairauksia?  Kyllä Ei 
 
Oletteko raskaana tai imetättekö?    Kyllä  Ei 
 
Oletteko allerginen tai yliherkkä jodille?    Kyllä Ei 
 
Käytättekö säännöllisesti tulehduskipulääkkeitä?   Kyllä Ei 
 
Jos vastasit edelliseen Kyllä, niin mitä ja kuinka 
usein:___________________________________ 
 
 
 
Tutkimuksessa Teidän tulee juosta juoksumatolla 90 minuuttia huomattavalla rasituksella, 
 
Salliiko terveytenne tutkimukseen osallistumisen?   Kyllä Ei 
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VATSAOIREKYSELY 
 
Vastaa vatsaoirekyselyyn ympyröimällä oikea vaihtoehto. 
 
1 = En koskaan 
2 = Harvoin (alle 10% kerroista) 
3 = Joskus (alle 50% kerroista) 
4 = Usein (yli 50% kerroista) 
5 = Aina (yli 90% kerroista) 
 
Kuinka usein kärsitte vatsavaivoista juostessanne tai heti juoksun jälkeen? 
 
1 2 3 4 5 
                               (En koskaan)                      (Aina) 
 
Oman juoksu-urasi aikana, oletteko kärsinyt näistä oireista juoksusuorituksen aikana tai heti sen  
jälkeen? 
 
Vatsakipu   1 2 3 4 5 
                  (En koskaan)                      (Aina) 
 
 
Pahoinvointi    1 2 3 4 5                                              (En 
koskaan)                      (Aina) 
 
 
Oksentelu        1 2 3 4 5                                              (En koskaan) 
                     (Aina) 
 
 
Turvotus   1 2 3 4 5                                              (En 
koskaan)                      (Aina) 
 
 
Röyhtäily   1 2 3 4 5                                              (En 
koskaan)                      (Aina) 
 
 
Ilmavaivat   1 2 3 4 5                                              (En 
koskaan)                      (Aina) 
 
 
Närästys    1 2 3 4 5                                              (En 
koskaan)                      (Aina) 
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Hölskyminen   1 2 3 4 5                                              (En 
koskaan)                      (Aina) 
 
Ripuli   1 2 3 4 5                                              (En koskaan) 
                     (Aina) 
 
Ummetus   1 2 3 4 5                                              (En 
koskaan)                      (Aina) 
 
Ulosteenne koostumus on juoksusuorituksen jälkeen yleensä (ympyröi oikea vaihtoehto): 
 
1 Löysä 
2 Ripuli 
3 Kova 
4 Normaali/kiinteä 
5 Normaali rakenne, mutta pakottava hätä 
 
 
Stressi aiheuttaa Teille vatsaoireita juoksusuorituksen aikana  Kyllä Ei  
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VATSAOIREET JA RAVINTOAINEET 
 
Vastaa vatsaoireita ja ravintoaineita koskeviin kysymyksiin ympyröimällä oikea vaihtoehto. 
 
1 = Ei koskaan 
2 = Harvoin (alle 10% kerroista) 
3 = Joskus (alle 50% kerroista) 
4 = Usein (yli 50% kerroista) 
5 = Aina (yli 90% kerroista) 
 
Onko Teillä laktoosi-intoleranssi?    Kyllä Ei 
 
Aiheuttavatko seuraavat ravintoaineet Teille vatsaoireita juoksusuorituksen aikana tai sen 
jälkeen? 
 
Kahvi  1 2 3 4 5 
               (Ei koskaan)                       (Aina)                                                                      
 
Alkoholi   1 2 3 4 5 
               (Ei koskaan)                       (Aina)                                                                      
                                             
Maitotuotteet  1 2 3 4 5 
               (Ei koskaan)                       (Aina)                                                                      
                                          
Hedelmät   1 2 3 4 5 
               (Ei koskaan)                       (Aina)                                                                          
 
Vihannekset   1 2 3 4 5 
               (Ei koskaan)                       (Aina)                                                                          
 
Leipä   1 2 3 4 5 
               (Ei koskaan)                       (Aina)                                                                          
 
Rasvaiset ruuat  1 2 3 4 5 
               (Ei koskaan)                       (Aina)                                                                      
 
Mausteiset / tuliset ruuat  1 2 3 4 5 
               (Ei koskaan)                       (Aina)                                                                      
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8.5 Supplement 5 
VATSAOIREKYSELY 
 
TUTKITTAVAN TIEDOT: 
 
Nimi: ______________________________________ 
 
Tutkimusnumero:____________________________ (projektitutkija täyttää) 
 
 
 
JUOKSUSUORITUKSEN JÄLKEEN TÄYTETTÄVÄKSI 
 
 
Merkitkää VAS-janalle juoksusuorituksen aikana kokemanne vatsakivun kovuus. 
 
 
                 
 
 
 
Ei kipua                    Pahin mahdollinen kipu 
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Kärsittekö juoksun aikana seuraavista vatsaoireista? Ympyröi oikea vaihtoehto. 
 
Pahoinvointi    Kyllä Ei 
 
Oksentelu    Kyllä Ei 
 
Turvotus    Kyllä Ei 
 
Röyhtäily    Kyllä Ei 
 
Ilmavaivat    Kyllä Ei 
 
Närästys    Kyllä Ei 
 
Hölskyminen    Kyllä Ei 
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MYÖHEMMIN TÄYTETTÄVÄKSI 
 
Kärsittekö juoksun jälkeen tai myöhemmin juoksusuorituspäivänä seuraavista vatsaoireista? 
Ympyröi oikea vaihtoehto. 
 
Vatsakipu    Kyllä Ei 
 
Pahoinvointi    Kyllä Ei 
 
Oksentelu    Kyllä Ei 
 
Turvotus    Kyllä Ei 
 
Röyhtäily    Kyllä Ei 
 
Ilmavaivat    Kyllä Ei 
 
Närästys    Kyllä Ei 
 
Hölskyminen    Kyllä Ei 
 
Ripuli    Kyllä Ei 
 
Ummetus    Kyllä Ei 
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Ulosteenne koostumus juoksusuorituksen jälkeen oli (ympyröi oikea vaihtoehto): 
 
1 Löysä 
2 Ripuli 
3 Kova 
4 Normaali/kiinteä 
5 Normaali rakenne, mutta pakottava hätä 
 
 
 
 
 
 
 
     
 
 
 
 
